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CHK2 IS NEGATIVELY REGULATED BY PROTEIN PHOSPHATSE 2A
Alyson K. Freeman
ABSTRACT
Checkpoint kinase 2 (CHK2) is an effector kinase of the DNA damage response
pathway and although its mechanism of activation has been well studied, the attenuation
of its activity following DNA damage has not been explored. Here, we identify the B'α
subunit of protein phosphatase 2A (PP2A), a major protein serine/threonine phosphatase
of the cell, as a CHK2 binding partner and show that their interaction is modulated by
DNA damage. B'α binds to the SQ/TQ cluster domain of CHK2, which is a target of
ATM phosphorylation. CHK2 is able to bind to many B' subunits as well as the PP2A C
subunit, indicating that it can bind to the active PP2A enzyme. The induction of DNA
double-strand breaks by ionizing radiation (IR) as well as treatment with doxorubicin
causes dissociation of the B'α and CHK2 proteins, however, it does not have an effect on
the binding of B'α to CHK1. IR-induced dissociation is an early event and occurs in a
dose-dependent manner. CHK2 and B'α can re-associate hours after DNA damage and
this is not dependent upon the repair of the DNA. Dissociation is dependent on ATM
activity and correlates with an increase in the ATM-dependent phosphorylation of CHK2
at serines 33 and 35 in the SQ/TQ region. Indeed, mutating these sites to mimic
phosphorylation increases the dissociation after IR. CHK2 is able to phosphorylate B'α
in vitro; however, in vivo, irradiation has no effect on PP2A activity or localization.
viii

Alternatively, PP2A negatively regulates CHK2 phosphorylation at multiple sites, as well
as its kinase activity and protein stability. These data reveal a novel mechanism for
PP2A to keep CHK2 inactive under normal conditions while also allowing for a rapid
release from this regulation immediately following DNA damage. This is followed by a
subsequent reconstitution of the PP2A/CHK2 complex in later time points after damage,
which may help to attenuate the signal. This mechanism of CHK2 negative regulation by
PP2A joins a growing list of negative regulations of DNA damage response proteins by
protein serine/threonine phosphatases.

ix

INTRODUCTION
DNA Damage Response Pathway
Maintenance of genomic integrity is an essential part of cellular physiology.
Genotoxic insults that induce DNA breaks must be repaired in order to prevent the
propagation of mutations that can contribute to malignant transformation. DNA damage
occurs via multiple mechanisms including ionizing radiation (IR), ultraviolet radiation
(UV), chemicals from the environment, replication stress, and reactive oxygen species
that are made as a byproduct of cellular metabolism. The primary role of the DNA
damage response (DDR) is to induce cell cycle arrest, repair the incurred DNA damage,
or, in cases where the extent of damage is beyond repair, signal for the initiation of
apoptosis or cellular senescence (214).
The different types of DNA damage as well as each repair mechanism were
extensively reviewed recently (153). Here, we will focus primarily on the DNA damage
induced by IR, which causes mainly double-strand breaks (DSB), UV which causes
single-strand breaks (SSB), and hydroxyurea (HU) which causes replication stress. DSB
can be repaired through non-homologous end joining (NHEJ) and homologous
recombination (HR) (60). The exact repair mechanism for stalled replication forks and
SSB in mammals has not been elucidated, but in yeast, it involves a special class of DNA
polymerases called translesion polymerases (139).
After a DNA break, the DDR must arrest the cell cycle to allow time for the DNA
to be repaired. Distinct cell cycle checkpoints include G1/S or G1, intra-S-phase, and
1

G2/M or G2. In the case that the damage cannot be repaired, the cell cycle arrest can lead
to senescence or the cell can signal through the apoptotic pathway (108, 130). Signaling
through the DDR occurs through a distinct pathway that includes sensors, signal
transducing proteins, effector kinases, mediators, and effector proteins (Figure 1).
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Figure 1. The DNA damage response pathway. DNA breaks and replication stress
signal through the sensors (MRN and 9-1-1), mediators (H2AX, BRCA1, MDC1,
53BP1), signal transducing kinases (ATM, ATR), effector kinases (CHK2, CHK1), and
effector proteins (E2F1, p53, Cdc25) leading to cell cycle arrest and gene transcription.
Proteins that are phosphorylated by ATM and/or ATR are marked by a gray phosphate
group and proteins that are phosphorylated by CHK2 and/or CHK1 are marked by a black
phosphate group. An arrow signals activation and a "T" signals inhibition.
3

Sensors - Mre11-Rad50-Nbs1 and Rad9-Rad1-Hus1 Complexes
DNA damage is recognized by sensor proteins that initiate the activation of the
DDR. These sensors include the Mre11-Rad50-Nbs1 (MRN) complex and the Rad9Rad1-Hus1 (9-1-1) complex that localize to DSB or regions of replication stress and SSB,
respectively (84, 139). These complexes are necessary for the activation of the signal
transducing kinases.
The structure of the 9-1-1 complex resembles the proliferating cell nuclear
antigen (PCNA) sliding clamp that is loaded onto DNA at points of replication (139).
The Rad17-replication factor C (RFC) complex acts as the 9-1-1 clamp loader in a
process analogous to RFC acting as the clamp loader for PCNA (11).
The MRN complex binds to DNA DSB. Mre11 binds to Nbs1, DNA, and Rad50
and possesses DNA exonuclease, endonuclease, and unwinding activities (196). Rad50
may function to keep the broken ends of the DNA together. Nbs1 functions to recruit
signal transducing kinases to the break site and mediates the DDR signal (215).

Signal Transducing Kinases - ATM and ATR
The localization of the MRN and 9-1-1 complexes to the sites of DNA damage
signals to the signal transducing kinases to become active. These kinases are Ataxiatelangiectasia mutated (ATM) and ATM and Rad3-related (ATR), which are members of
the PI-3K like kinase (PIKK) family with DNA-dependent protein kinase (DNA-PK).
Primarily in response to DSB, ATM is activated by autophosphorylation on
S1981 causing inactive dimers to dissociate into active monomers (7). Interestingly, the
ATM protein was first identified in patients with ataxia-telangiectasia (AT) (156). AT
4

causes genomic instability, a predisposition to cancer, immunodeficiency, and several
neurological impairments (33). Mutation of Mre11 and Nbs1 in humans causes the
similar disorders AT-like disorder (ATLD) and Nijmegen Breakage Syndrome (NBS),
respectively (172, 188). Nbs1 seemingly acts both upstream and downstream of ATM as
ATM is known to phosphorylate Nbs1 on S343 and at the same time Nbs1 and the MRN
complex have been shown to be required for full activation of ATM (81, 186, 215).
The localization of ATR to the break site and its subsequent activation is
dependent upon the 9-1-1 complex, binding between ATR and ATR-interacting protein
(ATRIP), and replication protein A (RPA). RPA coats single-strand DNA and consists of
3 subunits: RPA70, RPA32, and RPA14 (29). RPA32 is phosphorylated at T21 and S33
by ATM , ATR, and DNA-PK (12).
Although DNA-PK is not classified as a signal transducing kinase, it does play a
role in the DDR. DNA-PK is comprised of a catalytic subunit, DNA-PKcs, and the
targeting subunit, the Ku70-Ku80 heterodimer. It is activated upon association with
DNA (165). The primary role of DNA-PK is to initiate NHEJ to repair DNA doublestrand breaks. Two major autophosphorylation clusters in DNA-PKcs (referred to as
ABCDE and PQR) regulate the ability of DNA-PK to function in DNA end processing
during repair (117).

Effector Kinases - CHK1 and CHK2
The signal transducing kinases ATM and ATR signal through the effector kinases
CHK1 and CHK2 (checkpoint kinase 1 and checkpoint kinase 2) (8). CHK1 and CHK2
work alongside ATM and ATR to perpetuate the DDR signal. CHK2 is activated
5

primarily in response to DSB through the phosphorylation of T68 by ATM (3, 113, 119).
CHK1 is active even in unperturbed cells, but is also further activated through the
phosphorylation of S317 and S345 by ATR, primarily in response to SSB and replication
stress (8). Interestingly, there is also crosstalk between these two pathways. The
processing of DSB in an ATM- and Mre11-dependent manner leads to RPA coating the
single-stranded DNA, leading to activation of ATR and CHK1 (73). ATR can
phosphorylate and activate ATM following UV treatment or replication stress (174).
CHK1 S317 phosphorylation has been shown to be dependent on ATM and Nbs1 in
addition to ATR (53).
The importance of the effector proteins in development has been discovered using
mouse models. CHK1-deficient mice are embryonic lethal, however, CHK2-deficienct
mice are viable and do not have an increased risk for cancer (68, 100, 181, 182). This,
along with the fact that CHK1 is active under normal circumstances, leads some to the
belief that CHK1 acts as the "workhorse" of the cells and CHK2 functions only when
needed after DNA damage.

6

Mediators - H2AX, BRCA1, MDC1, and 53BP1
The mediator proteins H2AX, BRCA1, MDC1, and 53BP1 work to coordinate the
localization of various factors in the DDR, promote their activation, and regulate
substrate accessibility (176).
The histone variant H2AX comprises 10-15% of total cellular histone H2A, as
revealed through mouse studies (19). H2AX is phosphorylated by ATM, ATR, and
DNA-PK on S139 and is commonly referred to as γ-H2AX (148). γ-H2AX forms foci
both proximal and distal to the DSB site and is dephosphorylated following repair of the
DNA (reviewed in a following section), thus it is an excellent marker for the presence of
DSB (147). γ-H2AX is required for the foci formation of Nbs1 and the other mediator
proteins BRCA1, MDC1, and 53BP1, which is important for DDR signaling (9, 19, 140,
173, 178).
BRCA1 (breast cancer susceptibility 1) is phosphorylated by ATM on S1387 and
by CHK2 on S988 in response to IR (21, 32, 52). In response to UV, BRCA1 is
phosphorylated by ATR on S1457 (54). Phosphorylated BRCA1 forms distinct nuclear
foci that co-localize with γ-H2AX, MDC1, and the MRN complex. The role of BRCA1
seems to be to direct repair through both NHEJ and HR (166, 192).
MDC1 is phosphorylated in an ATM- and CHK2-dependent manner, binds to γH2AX and co-localizes with γ-H2AX foci, and is required for the formation of MRN,
BRCA1, and 53BP1 foci (103, 173, 177). Thus, MDC1 functions as a molecular scaffold
to mediate parts of the DDR downstream of foci formation (126).
53BP1 was first discovered based on its ability to bind to the DNA-binding
domain of p53 (70). In the DDR, 53BP1 localizes to the sites of DSB, is required for cell
7

cycle checkpoints, and is required for p53 accumulation and BRCA1 foci formation
(190). It seems to be involved in ATM activation, although the precise mechanism is not
known (125).

Effector Proteins - Cdc25, E2F1, and p53
The effector proteins Cdc25, p53 and E2F1 function to activate cell cycle
checkpoints and regulate the transcription of genes whose products are important in the
end result of the DDR, whether it be DNA repair, apoptosis, or senescence.
The Cdc25 phosphatases regulate progression through the cell cycle by removing
inhibitory Y15 phosphatases from the cyclin-dependent kinases Cdk1 and Cdk2 (38).
The negative regulation of Cdc25 leads to G1/S, intra-S, and G2/M checkpoints. CHK1
phosphorylates Cdc25A on S76, leading to Cdc25A ubiquitination and degradation (74).
CHK1 and CHK2 phosphorylate Cdc25C on S216 which allows 14-3-3 binding and
subsequent sequestration of Cdc25C in the cytoplasm, away from substrates. Cdc25B1
and Cdc25B2 are phosphorylated on S309 and S323, respectively, leading to inactivation
through the same 14-3-3-mediated mechanism (38, 210).
The transcription factor p53 may be the most widely recognized tumor suppressor
and has been found to be mutated in more than half of all tumor cases (62). In addition,
the multi-organ cancer syndrome, Li-Fraumeni syndrome, is caused in most cases to be
from inheritance of a mutant copy of the p53 gene, TP53, and subsequent loss of the
wild-type copy (109, 170).
P53 is stabilized in the DDR which allows it to activate the transcription of genes
whose products participate in cell cycle arrest, DNA repair, senescence, or apoptosis,
8

depending upon the cellular stress (63). Mdm2 negatively regulates p53 through
ubiquitin-mediated proteosomal degradation (64, 69, 78). MdmX also negatively
regulates p53 by binding to Mdm2 and enhancing Mdm2 binding to and ubiquitination of
p53 (98, 143, 185). ATM, ATR, DNA-PK, CHK1 and CHK2 stabilize p53 by direct
phosphorylation on S15 and S20 which prevent p53 binding to Mdm2 (5, 160, 161).
ATM and ATR inhibit Mdm2 by phosphorylating it on S395 and S407, respectively (114,
162). ATM phosphorylates MdmX on S403 which leads to its ubiquitination and
degradation (141). CHK2 phosphorylates MdmX on S367 and S342 which promotes 143-3 binding and degradation of MdmX (24, 82). Therefore, multiple DDR proteins
coordinate to stabilize and activate p53 through phosphorylation of p53 and its negative
regulators Mdm2 and MdmX.
The transcription factor E2F1 is also activated in the DDR. ATM and CHK2
phosphorylate E2F1 on S31 and S364, respectively, which leads to E2F stabilization (97,
171). E2F1 can then upregulate genes that lead to cell cycle checkpoints or apoptosis,
although the specific genes that are responsible for these cellular effects have not yet
been determined.

9

Checkpoint Kinase CHK2
The functions of CHK2 in phosphorylating and activating factors in the DDR are
outlined above. This section will focus on the details of CHK2 structure and activation,
its mutations found in cancer, and the pursuit of a CHK2 cellular phenotype.

CHK2 Structure and Activation
CHK2 contains three major domains (Figure 2): an SQ/TQ domain (amino acid
residues 19-69), an FHA domain (amino acid residues 112-175), and a serine/threonine
kinase domain (amino acid residues 220-486), all of which play a role in the activation of
CHK2. The SQ/TQ domain contains seven serine or threonine residues followed by a
glutamic acid. SQ and TQ sites are preferentially phosphorylated by ATM and ATR (77,
132). The FHA domain recognizes and binds to phosphorylated proteins and therefore
mediates protein-protein interactions (41). The kinase domain is the enzymatically active
domain and is responsible for the phosphorylation of serine and threonine residues of
CHK2 substrates.
Under normal conditions, CHK2 exists as a monomer (2). In response to DNA
damage, ATM phosphorylates CHK2 on T68 in the SQ/TQ domain (3, 113, 119). The
FHA domain of one molecule of CHK2 binds to the phosphorylated T68 of another,
allowing autophosphorylation of T383 and T387 within the kinase domain (83, 200).
CHK2 then dissociates into active monomers (2). CHK2 is also phosphorylated at
serines 19, 33, and 35 in the SQ/TQ domain by ATM and autophosphorylated at S516
and these events enhance CHK2 activity (16, 79, 124, 198). Phosphorylation of CHK2 at
S456 regulates CHK2 stability and autophosphorylation at S379 leads to CHK2
10

ubiquitination and positively affects CHK2 function (75, 104). Of note, a useful tool in
studying CHK2 has been the D347A dominant negative kinase-dead mutant (22, 112).
The crystal structures of the FHA and kinase domains, alone and together, have
been solved, which has proven extremely informative for deciphering the specific
residues necessary for the oligomerization and activation of CHK2 as well as binding
between CHK2 and its substrates (17, 95, 137). Attempts to crystallize full length CHK2
have been unsuccessful due to the fact that the SQ/TQ domain is highly susceptible to
digestions, suggesting that it is unstructured or loosely folded (17). In order to crystallize
the kinase domain of CHK2 and preserve the ability to form dimers, a small-molecular
inhibitor or a kinase-dead mutant needed to be used, since active CHK2 dissociates into
monomers (17, 137).
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Figure 2. The structure of CHK2. The SQ/TQ domain is displayed in light gray, the
FHA domain in dark gray, and the kinase domain in black. Important CHK2
phosphorylation sites are highlighted.
12

CHK2 in Cancer
CHK2 is considered a tumor suppressor and mutations in CHEK2, the gene
encoding human CHK2, have been found in various cancers. The first mutation found in
CHEK2 was 1100delC, originally identified in families with Li-Fraumeni syndrome that
did not have mutations in TP53 (10). Later, this mutation was also found to be
significantly associated with breast cancer in familial cases without a BRCA1 or BRCA2
mutation (187). This CHEK2 allele seems to act as a low-penetrance tumor suppressor
gene and may be an adverse indicator of prognosis (34, 118). The SUM102PT breast
cancer cell line contains the 1100delC mutation (195).
Many other mutations in CHK2 have also been identified, but the clinical
significance of most are not yet clear. I157T and 1422delT were found in Li-Fraumeni
families lacking a TP53 mutation (10). R180H, R117G, R137Q, and delE161 were
identified in breast cancer patients with familial history (167, 168). Y424H and S428F
were found in Ashkenazi Jewish families with a high risk of breast cancer (80, 159).
R145W was identified in the HCT15 colon carcinoma cell line (10). The nucleotide
mutation T908A was found in the UACC812 breast cancer cell line (195). In addition,
multiple germline CHEK2 mutations have been found in prostate cancer patients and
families with familial prostate cancer (37). CHK2 transcriptional downregulation due to
promoter methylation has also been identified in human cancers (191, 212).
The 1100delC mutation causes a frameshift at amino acid T366 and the 1422delT
causes a frameshift at amino acid R475, both of which result in an early stop codon (10).
These mutants have no kinase activity in vitro (199). The T908A mutation also causes an
early stop codon at L303 (195). R145W has reduced kinase activity in vitro, is not
13

phosphorylated at T68, cannot be activated in response to IR, and cannot bind to p53 in
vivo (46, 199). The R145W mutation also leads to a destabilization and degradation of
the CHK2 protein (85). I157T cannot bind to p53 in vivo, has reduced kinase activity in
vitro, and has deficiencies in CHK2 oligomerization and autophosphorylation (46, 158,
199). This is most likely due to the fact that this site plays an integral role in the FHAkinase domain interface during CHK2 activation (17). 1100delC and E161del are
unstable and not efficiently phosphorylated at T68 following IR whereas R117G is
phosphorylated at T68 but does not display a mobility shift via Western blot, suggesting
it is not phosphorylated fully at other sites that are necessary for the activation of CHK2
(169). S428F could not complement a Rad53 (CHK2 homologue) deletion in S.
cerevisiae and therefore is thought to abrogate CHK2 function (159). R117G, R145W,
and E161del are likely to be deleterious to CHK2 function based on a bioinformatics
analysis of CHK2 peptides from nine species (169).
The germline mutations 1100delC and R145W are associated with loss of the
wild-type allele (85). The HCT15 cell line, which harbors the R145W mutation on one
CHEK2 allele, has heterozygous inactivation of CHK2 (85). Using reverse transcriptasePCR, the only detectable CHEK2 gene in the HCT15 cell line harbored the mutation
which causes the expression of the R145W protein and therefore, HCT15 cells lack
functional CHK2 (46). The SUM102PT and UACC812 breast cancer cell lines also lack
detectable CHK2 protein levels (195).
In summary, mutations in CHK2 have been found that affect protein function in a
number of ways. Many mutations have been identified in Li-Fraumeni families, primary
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human cancers, and cancer cell lines, although more work needs to be done to elucidate
the effects on CHK2 function as well as the clinical significance of these mutations.

CHK2 Phenotypes
Two CHK2-/- mouse models have given much information about the importance
of CHK2 in specific aspects of the DDR. Surprisingly, given the many actions of CHK2,
it was not found to be necessary for organism development, whereas CHK1-null mice are
embryonic lethal (68, 100, 181, 182). It is possible that since CHK2 and CHK1 share
many targets, the absence of CHK2 may be compensated for by CHK1. Here, the
phenotypes of cells lacking CHK2 will be discussed.
In one CHK2 mouse model, CHK2-/- MEFs (mouse embryonic fibroblasts) and
ES (embryonic stem) cells in a C57BL/6 background displayed a normal G2/M
checkpoint following IR. Initiation of the G1/S checkpoint was intact but cells were
deficient in maintenance of the checkpoint (181). In contrast, in another mouse model,
thymocytes from CHK2-/- mice in the same background displayed a decrease in G1/S
arrest, G2/M arrest, and apoptosis following IR (68).
Using HCT15 cells expressing HA-tagged CHK2, CHK2 was shown to play an
integral role in the intra-S-phase checkpoint (47). Cells lacking functional CHK2
continued to replicate DNA after DSB instead of activating an intra-S-phase checkpoint
in a phenotype called radioresistant DNA synthesis (RDS). This is due to the inability to
induce the degradation of Cdc25A.
Surprisingly, CHK2 was found to be not required for the p53-mediated DDR
response. Knockdown of CHK2 in HCT116 cells inhibited Cdc25C phosphorylation at
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S216 but had no effect on p53 stabilization or phosphorylation on S20 following
neocarzinostatin (NCS) treatment, which causes DSB (1). CHEK2 in the HCT116 cell
line was disrupted using gene targeting (71). HCT116 CHK2-/- cells displayed normal
p53 accumulation and phosphorylation at S20 in response to IR, intact G1/S and G2/M
checkpoints following IR, and an appropriate apoptotic response to 5-fluorouracil when
compared to the HCT116 wild-type cells. Gene targeting was also used to generate
CHK2-deficient chicken DT40 cells (144). These cells prematurely entered mitosis
following IR and therefore were defective in the G2/M checkpoint.
These often contradictory results demonstrate the difficulties in clearly
demonstrating a cellular phenotype for cells lacking CHK2. CHK2 function appears to
be dependent on cell type and mechanism of induction of DNA damage. In the literature,
the function of CHK2 in cells is often measured by RDS, apoptosis, and the G1/S and
G2/M checkpoints.
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Protein Serine/Threonine Phosphatases
There are two major families of protein serine/threonine phosphatases (PSP). The
phosphoprotein phosphatases (PPP) include protein phosphatases (PP) PP1, PP2A, PP2B,
PP4, PP5, PP6, and PP7 and the metal-dependent protein phosphatases (PPM) include
PP2C.
Four isoforms of PP1 are derived from three genes and PP1 is regulated by
interactions with many proteins (189). PP2A consists of an A structural subunit, a C
catalytic subunit, and one of many B regulatory subunits, described in detail in the
following section. PP4 and PP6 are closely related to PP2A C. The holoenzyme of PP6
is proposed to consist of the PP6 catalytic subunit, a SAPS subunit and an ankyrin repeat
subunit (123). PP2B, also known as PP3 and calcineurin, and PP7 are stimulated by
Ca2+. PP2B consists of an A catalytic subunit and a B subunit that is related to
calmodulin. PP7 contains EF-hand domains (127). PP5 is unique in the fact that it has
three TRP domains, which mediate protein-protein interactions, and a peptidyl-prolyl cistrans isomerase-like domain that are not present in any other PPP (67).
PPM proteins require Mg2+ or Mn2+ for enzymatic activity. There are at least 18
genes encoding PP2C proteins. PP2Cδ is also known as Wip1 or PMDD1. Wip1,
PP2Cα, PP2Cβ, and PP2Cγ have regions of high similarity (107).

PP2A Structure and Regulation
The active PP2A holoenzyme is comprised of three subunits: a structural A
subunit (PR65), a catalytic C subunit, and a B subunit (Figure 3). There are two forms of
the A subunit, α and β, that have 87% identity (66). There are also two forms of the C
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subunit, α and β, which share 97% identity (175). The B subunits can be divided into
four major families: the B (PR55), B' (PR61/B56), B'' (PR72), and B'''
(PR93/PR110/striatins). These regulatory subunits are transcribed from 15 genes that
encode at least 26 differentially spliced isoforms (42). The B subunits are thought to
confer to PP2A its functional specificity (189).
The crystal structure of the holoenzyme containing PP2A Aα, Cα, and B'γ1 was
solved, revealing the active enzyme structure as well as binding sites between the three
subunits (25, 201). The Aα subunit contains 15 HEAT repeats of antiparallel α-helices
and forms a horseshoe shape. The Cα subunit forms a compact ellipsoidal structure. The
B'γ1 subunit forms a shape similar to the Aα subunit and is comprised of 18 α-helices
and 8 pseudo-HEAT repeats.
The full B' family was originally cloned in 1995 and is comprised of five genes,
two of which are differentially spliced to form three isoforms each (116). The names of
all of the B' family members are as follows: B'α, B'β, B'ε, B'δ1, B'δ2, B'δ3, B'γ1, B'γ2,
and B'γ3. Although this nomenclature is the most commonly used, some laboratories use
older nomenclature for certain B' proteins, using the same Greek letters, but these names
do not match up with the current naming system. Therefore, the literature of the B'
family can often be confusing. In this document, we will only refer to the most common
naming for uniformity and therefore it may differ from the terminology used in the
original publications.
Various mechanisms of PP2A activity regulation have been discovered.
Phosphorylation of PP2A C at Y307 results in inactivation of the enzyme (23).
Methylation of the PP2A C subunit at L309 regulates binding to the B family members,
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but not B' or B'' proteins, which likely affects PP2A substrate specificity (102). The
serine/threonine kinase PKR phosphorylates B'α and this increases PP2A activity in vitro
(202). Therefore, in addition to substrate specificity based on the B subunit in the
holoenzyme, post-translational modifications can affect PP2A activity.
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Figure 3. PP2A holoenzyme structure. The A structural subunit binds to the C
catalytic subunit and one of many B regulatory subunits to form a holoenzyme complex.
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PP2A Function
The PP2A C subunit is an abundant protein, making up 0.1% of total cellular
protein (189). PP2A participates in diverse cellular processes such as differentiation, cell
cycle regulation, and signal transduction (72). A few key roles of PP2A, focusing on the
role of the B' family, will be discussed here, however, an exhaustive list of proteins that
have been shown to bind to PP2A directly can be found in a recent review (42). The
specific roles of PP2A in the DDR are detailed in a following section.
Several PP2A mouse models have illuminated the importance of PP2A in cell
growth and embryonic development. Knockout of the gene encoding PP2A Cα results in
embryonic lethality (56). Transgenic mice overexpressing B'γ in the lung die neonatally
and lack proper lung development (45). A dominant negative PP2A A mutant that lacks
the ability to bind to the B subunits causes dilated cardiomyopathy and often premature
death in transgenic mice expressing the protein in muscle (14).
C-Myc is transcription factor that regulates genes involved in cell growth,
differentiation, and apoptosis. The overexpression of c-Myc has been found in many
human tumors (31). PP2A containing B'α binds to c-Myc and dephosphorylates it at
S62, resulting in decreased c-Myc protein levels and decreased c-Myc transcriptional
activity (6).
PP2A has a negative effect on the G2/M transition through the negative regulation
of Cdc25 (30, 86). In order to achieve full activation of Cdc25C for entry into mitosis, it
is phosphorylated at T138, which causes removal of 14-3-3. PP2A containing B'δ
counteracts this by dephosphorylating T138 in Cdc25C. Chk1 phosphorylates PP2A B'δ
at S37, enhancing B'δ binding to the A and C subunits. Therefore, Chk1 keeps the cell
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from progressing into mitosis by enhancing dephosphorylation of T138, keeping 14-3-3
bound (110).
The apoptotic agent ceramide was shown to induce apoptosis through
mitochondrial PP2A dephosphorylation of Bcl2 at S70, which enhances its activation
(152). This is mediated by the B'α subunit and ceramide promotes translocation of B'α
to the mitochondrial membrane (151).

PP2A in Cancer
Several independent lines of evidence suggest a role for the PP2A holoenzyme as
a tumor suppressor and indicate the importance of inhibiting PP2A function in cellular
transformation. The SV40 small T antigen can bind to the PP2A A-C complex in place
of a B subunit, inhibiting PP2A activity, and this interaction is required for SV40mediated transformation (61, 138, 204). Okadaic acid (OA), a known PP2A inhibitor,
was also found to promote tumor formation (179).
Somatic mutations in the gene encoding the PP2A Aβ subunit, PPP2R1B, were
found in 15% of primary lung tumors, 15% of primary colon tumors, and 6% of lung
tumor-derived cell lines (194). Five missense mutations in PPP2R1B leading to amino
acid substitutions (G15A, L499I, V498E, V500G, and S365P) were found in four colon
carcinomas (180). The PP2A Aα mutations E64D in a lung carcinoma, E64G in a breast
cancer, R418W in a melanoma cell line, and a frameshift mutation at amino acid F170 in
a breast cancer were recently identified (18). These mutations prevent binding to the B'
or B and C subunits (44, 150). In addition, several cancer cell lines have reduced
expression of the A subunit as compared to primary normal epithelial cells (216).
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Protein Serine/Threonine Phosphatases in the DNA Damage Response
Phosphorylation plays an integral role in the positive and negative regulation of
the DNA damage response pathway signaling, as described above. Interestingly,
phosphatases are increasingly being shown to play integral roles in the positive and
negative regulation of the cellular signaling in response to different DNA damages. This
section will review the recent literature implicating the importance of phosphatases in the
DDR alongside kinases.

DNA Damage Response Proteins that are Negatively Regulated
Since much of the signaling of the DNA damage response pathway is regulated
by serine and threonine phosphorylation, it is intuitive that PSPs would negatively
regulate these phosphorylation events. Indeed, there are many proteins that are
negatively regulated in this manner (Figure 4).
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Figure 4. Protein serine/threonine phosphatases in the DNA damage response
pathway. The positive and negative regulation of DDR proteins via PSPs is shown. An
arrow indicates activation and a "T" indicates inhibition.
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ATM and ATR
The first evidence that PP2A might play a role in the ATM-dependent DDR came
from the finding that the PP2A B subunit dissociates from the PP2A heterotrimer in the
nucleus in an ATM-dependent manner after IR (58). It was later found that inhibition of
PP2A with OA or expression of a dominant-negative PP2A C increased ATM
autophosphorylation at S1981 under normal conditions, but did not affect ATM activity.
ATM binds to the A and C subunits, but this binding is dissociated after IR, partially in
an ATM-dependent manner (55). PP2A was able to dephosphorylate ATM S1981, but
not as efficiently as Wip1, described below (163).
The PP2A interacting protein TIP binds directly to PP2A C and inhibits PP2A
activity. PP2A was found to oppose the ATM and ATR phosphorylation of a 32kD
protein and TIP prevented this function of PP2A (115). In X. laevis nucleoplasmic
extracts, DSB inhibit replication by inhibiting the loading of Cdc45, RPA, and
polymerase α onto DNA. However, PP2A and caffeine, an inhibitor of ATM and ATR,
was able to reverse the inhibition of replication and restore loading of the necessary
factors (142).
Two different Wip1 mouse models have shown a role for Wip1 in negatively
regulating ATM. E1A+Ras expressing Wip1-null MEFs were seen to have an increase in
ATM phosphorylation at S1987 (human S1981) and ATM activity under normal
conditions as well as after IR. Phosphorylation of p53 S18 (human S15), the ATM
phosphorylation site, was increased slightly as well (163). Splenocytes from Wip1+/- and
Wip1-/- mice in an Eµ-myc background displayed an increase in ATM phosphorylation
and p53 S18 phosphorylation (164). Wip1+/- and Wip1-/- mice were more resistant to
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tumor formation and this was dependent on ATM and p53 (164). Wip1 was found to
dephosphorylate ATM at S1981, S367 and S1893 in vitro (163, 164).
In human cells, the overexpression of Wip1 decreased ATM autophosphorylation
and ATM-dependent CHK2 phosphorylation after IR. The induction of Wip1 protein
levels in control cells correlated with the decrease in phosphorylated ATM after IR.
ATM phosphorylation also remained longer after IR in cells that had decreased Wip1.
Wip1 could dephosphorylate ATM S1981 in vitro (163). Another study, however, used a
tetracycline-inducible Wip1 and showed that the expression of Wip1 after IR did not
have an effect on S1981 phosphorylation (106). This difference may be due to the
different cell lines and conditions used.

RPA
After treatment with and removal of HU, RPA32 is dephosphorylated at S21 and
S33. Inhibition of PP2A with OA or knockdown via siRNA results in persistence of RPA
phosphorylation and foci. An RPA mutant that could not be dephosphorylated resulted in
reduced cell viability following UV or HU treatment and reduced DNA repair following
replication stress (48). This implicates PP2A in the recovery of the DDR.

CHK1
CHK1 has been shown to be negatively regulated by multiple PSPs. In S. pombe,
the PP1 homologue Dis2 negatively regulates CHK1. Cells lacking Dis2 have a
prolonged G2 arrest following treatment with the double-strand break inducer MMS
(methylmethane sulfonate) or the UV mimetic 4-NQO (4-nitroquinoline-N-oxide) but
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DNA repair is not affected. The overexpression of Dis2 caused a decrease in CHK1
activation following UV (35). CHK1 S345 could be dephosphorylated in vitro by Dis2
or human PP1 (35, 106).
In human cells, the inhibition of PP2A induced CHK1 phosphorylation in the
absence of DNA damage and also prevented CHK1 dephosphorylation after HU removal.
The knockdown of PP2A increased CHK1 phosphorylation on S317 and S345 and in
vitro, PP2A was able to directly dephosphorylate CHK1 (88). In X. laevis egg extracts,
the addition of PP2A C reversed CHK1 phosphorylation at S344 (human S345) after
activation by DSB. The inhibition of PP2A also enhanced CHK1 phosphorylation
following activation by DSB (142).
Human CHK1 is also regulated by Wip1. Wip1 could dephosphorylate CHK1
primarily at S345 and slightly at S317 in vitro. In vivo, the overexpression of Wip1
resulted in the elimination of CHK1 phosphorylation at S345 and S317, a decrease of
Cdc25C phosphorylation at S216, a decrease in Cdk1 phosphorylation at Y15, and a
decrease in the S-phase and G2/M checkpoints, whereas the knockdown of Wip1 via
siRNA caused the reverse effects. Breast cancer cell lines with overexpression of Wip1
(MCF-7, BT474, and MDAMB231) showed only a marginal increase in CHK1 S345
phosphorylation after UV as compared to the control cells (HEK and U2OS) (106).
Interestingly, Wip1-/- MEFs in a 129/sv-C57BL6 background showed a greater increase
in phosphorylation at S345 in CHK1 after IR than wild-type MEFs whereas Wip1+/+ and
Wip1-/- splenocytes expressing Eµ-myc did not show any difference in Chk1 S345
phosphorylation, possibly indicating a cell type specific or DNA damage specific
regulation of CHK1 via Wip1 (106, 164).
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In summary, CHK1 phosphorylation at S317 and S345 and CHK1 activity
following DNA damage are regulated by PP1, PP2A, and Wip1. This seems to play an
important role in recovery from the DDR checkpoints.

CHK2
Much of the work examining the negative regulation of CHK2 has been done
using the S. cerevisiae CHK2 homologue Rad53. The PP2C phosphatases Ptc2 and Ptc3
as well as the type 2A phosphatase Pph3 have all been shown to negatively regulate
Rad53 under different circumstances. To study double-strand breaks in yeast, a system
that induces the HO endonuclease to create a single double-strand break at a specific
locus that cannot be repaired by homologous recombination was utilized (57). A single
break will cause a G2/M arrest and then adaptation to the checkpoint. Cells lacking Ptc2
and/or Ptc3 were defective in adaptation to an HO-induced G2/M arrest. Ptc2 and Ptc3
were required for recovery from the checkpoint as measured by Rad53 dephosphorylation
and release from the G2/M checkpoint. Ptc2 and Ptc3 bind to the FHA1 domain of Rad53
and protein kinase CK2 phosphorylation of Ptc2 at T376 is necessary for this interaction
(57, 87). Mutation of this site prevented adaptation and recovery of the G2/M checkpoint
(57). Therefore, Ptc2- and Ptc3-mediated dephosphorylation of Rad53 results in recovery
from the G2/M checkpoint.
Also in S. cerevisiae, deletion of the PP2A-like phosphatase Pph3 caused
hypersensitivity to MMS. Pph3-Psy2 binds to Rad53 and dephosphorylates it directly.
The Pph3-Psy2 complex is necessary for the dephosphorylation of Rad53 during

28

recovery from the intra-S-phase checkpoint and it promotes the resumption of normal
DNA synthesis following removal of MMS (131).
One study attempted to differentiate the roles of Pph3, Ptc2, and Ptc3 in
negatively regulating Rad53. Cells lacking Pph3 again showed hyperphosphorylation of
Rad53, but Rad53 was still deactivated after MMS treatment. Cells lacking Pph3, Ptc2,
and Ptc3 have impaired Rad53 deactivation following MMS treatment, although Rad53
deactivation from replication stress is only slightly delayed. Pph3 is not required for
Rad53 dephosphorylation and deactivation following replication stress. Ptc2 and Ptc3
were not required for Rad53 deactivation and dephosphorylation following genotoxic
stress in S-phase via HU (184). Thus, distinct phosphatases appear to be required for the
dephosphorylation and deactivation of Rad53 following various DNA damages and the
phosphatase required for recovery from replication stress has not yet been identified.
In humans, CHK2 was also found to be regulated by PP2A and Wip1. Inhibition
of PP2A using OA increased the phosphorylation of CHK2. Although PP2A was also
found to negatively regulate ATM, the effect on CHK2 phosphorylation is ATMindependent (55). Utilizing a yeast two-hybrid system, an in vitro binding assay, and coimmunoprecipitation, CHK2 was found to bind to PP2A A, C, and many B' subunits.
CHK2 was able to phosphorylate B'γ1 and B'γ3 in vitro and this increased PP2A activity
in vitro. The overexpression of B'γ3 resulted in a decrease in CHK2 phosphorylation
after adriamycin treatment, which causes DNA adducts (40). Following cisplatin
treatment, PP2A containing a B subunit was found to bind to CHK2. Inhibition of PP2A
with OA or knockdown via siRNA caused an increase in CHK2 phosphorylation at T68.
PP2A was found to dephosphorylate CHK2 in vitro as well (96).
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Wip1 and CHK2 bind in the nucleus and binding is dependent upon the CHK2
SQ/TQ domain, kinase activity, and nuclear localization signal (NLS) and the Wip1 Nterminal domain (50, 206). Endogenous Wip1 and CHK2 can bind in MCF7 cells, which
have a higher expression level of Wip1 and in A549 cells (50, 206). Using GST-Wip1 in
a GST pulldown assay with lysates of HCT15 cells stably expressing HA-CHK2, Wip1
was seen to bind to CHK2 only after IR, suggesting that CHK2 phosphorylation is
important for the interaction (136). In vitro, Wip1 can dephosphorylate CHK2 at S19,
S33/35, T68, T432, and S516 and this significantly reduces CHK2 kinase activity (50,
136). Overexpression of Wip1 inhibited CHK2 kinase activity in vitro, and in vivo,
decreased T68 phosphorylation, caused a delay in CHK2 activation following IR, and
caused a delay in G2/M arrest (50, 136). Knockdown of Wip1 resulted in sustained
CHK2 T68 phosphorylation and kinase activity following IR, as well as an increase in
apoptosis (50). In the acute promyelocytic leukemia (APL) cell line NB4, arsenic
trioxide could induce CHK2 T68 phosphorylation through the inhibition of Wip1 (205).
Finally, in stomach adenocarcinoma tumors, high Wip1 expression correlated with low
CHK2 phosphorylation (51).
In yeast, Rad53 is negatively regulated by PP2A-like and PP2C-like
phosphatases. In humans PP2A and the PP2C phosphatase Wip1 have been shown to
negatively regulate CHK2. These phosphatases have been demonstrated to negatively
regulate the activation of CHK2 as well as dephosphorylate it to allow for recovery from
DDR checkpoints.
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H2AX
PP1, PP2A and PP4 have been implicated in negatively regulating γ-H2AX. In
yeast, deletion of any of the PP4-like complex HTP-C genes (Pph3, Psy2, and Ybl046w)
increases the amount of cellular γ-H2AX. HTP-C can dephosphorylate γ-H2AX in vitro.
Although Pph3 deficient cells had similar rates of DSB repair and loss of γ-H2AX foci as
wild-type cells, even though H2AX remained phosphorylated, Rad9 (human 53BP1) and
Rad53 (human CHK2) remained active longer and this correlated with maintenance of
the G2/M checkpoint (76).
In human cells, the inhibition of PP1 partially inhibited the elimination of γH2AX after DNA damage induced by IR (129). The inhibition of PP2A or knockdown
with siRNA increased the amount of γ-H2AX, increased the amount of foci-positive
cells, increased the intensity of the foci, and increased the amount of time the foci were
maintained following treatment with the topoisomerase I inhibitor camptothecin (CPT)
(27). Although PP1 has been shown to dephosphorylate γ-H2AX in nucleosomes in
vitro, PP2A is at least 25 times more active toward γ-H2AX in monomeric form or when
incorporated into nucleosomes (27, 129). Indeed, PP2A C co-localizes with and binds to
γ-H2AX after CPT treatment and the binding increases with increasing DNA damage
(27).
Thus far, PP2A and PP4 have been implicated in negatively regulating γ-H2AX.
In cells with both PP4C and PP2A C knocked-down, γ-H2AX levels were higher and
sustained longer after CPT as compared to control cells, although the PP2A C
knockdown had a greater effect. PP2A C and PP4C had comparable abilities to
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dephosphorylate γ-H2AX from mononuclosomes in vitro (28). Both PP2A and PP4, but
not PP1, can dephosphorylate γ-H2AX in vitro from acid extracted histones. Knockdown
of PP4C and PP2A C caused an increase in the total levels of γ-H2AX in untreated and
irradiated cells (128).
Further examination of the specific roles of PP2A and PP4 in the regulation of γH2AX has found distinct roles for each. PP4C silenced cells, but not PP2A silenced
cells, showed an increase in γ-H2AX even before DNA damage (28). PP2A C silenced
cells were slightly weakened in the ability to repair DSB induced by X-rays but PP4C
silenced cells were not impaired in DNA repair. Knockdown of PP4C caused a slower
decrease in γ-H2AX foci after IR but PP2A knockdown did not affect foci. PP4C
primarily dephosphorylated γ-H2AX associated with chromatin rather than in the
nucleoplasm, whereas PP2A did not. PP4C depleted cells delayed entry into mitosis, but
did not have any problems with the initiation of the G2/M checkpoint (128).
In summary, the dephosphorylation of γ-H2AX is mediated through PP2A and
PP4. This is necessary for the recovery from the DSB-induced checkpoint.

P53
P53 is negatively regulated through direct dephosphorylation by PP1 and PP2A
and through the regulation of its negative regulator, Mdm2. The phosphorylation of p53
at S37 is required for p53 transcriptional activity. PP2A binds to p53 following IR and
dephosphorylates S37 (36). Inhibition of PP2A with OA or siRNA causes an increase in
p53 phosphorylation at S15 and an increase in p53 activity (121).
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By inhibiting PP1 and PP2A with 100nM OA and comparing to the inhibition of
only PP2A with 10nM OA, it was shown that PP1 inhibition induces apoptosis in rabbit
lens epithelial cells. This is accompanied by an induction of p53 and the p53 target Bax
(89). Inhibition of PP1, but not PP2A, with OA or calyculin A increased apoptosis in
human lens epithelial cells in a p53-dependent manner. Inhibition of PP1 only slightly
increased p53 levels but dramatically increased p53 phosphorylation at S15 and S37
which enhance regulation of p53 targets Bcl2 and Bax. PP1 dephosphorylates p53 at S15
and S37 in vitro and in vivo and this decreases its transcriptional activity and attenuates
apoptosis (90).
Wip1 is induced in response to IR in a p53-dependent manner as a part of a
negative feedback mechanism (26, 49). Wip1-/- MEFs exhibit a slight increase in p53
phosphorylation at S15 and an increase in the levels of p53 target p21 (26). In an in vitro
assay, Wip1 could dephosphorylate p53 on S15 but not S46. After IR, Wip1-/- MEFs had
an increase in phosphorylated S15. An increase in the protein levels of Wip1 decreased
p53 protein levels and S15 phosphorylation whereas knockdown of Wip1 with siRNA
resulted in increased p53 protein levels and S15 phosphorylation. In this system, Wip1
did not have an effect on ATM or ATR after IR or UV, respectively, therefore the effect
on p53 seems to be direct (106).
Wip1 plays an important role in the cell growth and cycle checkpoints in a p53dependent manner. Overexpression of Wip1 led to a decrease in colony formation (49).
Wip1-/- mice displayed a defect in T cell maturation due to sustained p53 activation (157).
Wip1-/- MEFs have a more robust G1 arrest following IR, which may be due to increased
activity of p53 (26). Wip1 was required for recovery from arrest in G2 in a p5333

dependent manner (99). Overexpression of Wip1 decreased the S-phase and G2/M
checkpoints whereas siRNA knockdown of Wip1 increased the intensity and length of the
S-phase and G2/M checkpoints after UV and IR (106). Interestingly, the Wip1 gene was
found to be amplified in 11% of human breast tumors, most of which had wild-type p53
(15). These data collectively suggest that the negative regulation of p53 by Wip1
contributes to tumorigenesis.
Not only is p53 regulated by multiple PSPs directly, but it is also regulated
indirectly through the regulation of Mdm2. Mdm2 was predicted to be a Wip1 substrate
(203). Indeed, Wip1, but not PP2A, dephosphorylates Mdm2 at S395, which is an ATM
phosphorylation site (105, 114). Wip1 dephosphorylation at S395 increases the stability
of Mdm2 and increases the Mdm2-p53 interaction. Wip1 inhibits Mdm2 autoubiquitination thereby stabilizing the protein (105).
The induction of p53 causes an induction of cyclin G and increased binding
between cyclin G and PP2A B'γ3 (134). Cyclin G preferentially associates with B'γ3 in
the active holoenzyme complex. It appears to act as a recruitment factor to bring PP2A
to Mdm2 so PP2A can dephosphorylate Mdm2 at S216 and S166. This increases Mdm2
binding to p53, thereby negatively regulating it (135). Overexpression of PP2A B'γ3 and
B'γ2 increases the levels of cyclin G1 protein. Ectopic expression of B'γ3 counteracts the
DNA damage-induced destabilization of cyclin G1 (92).
In conclusion, the multiple modes of regulation of p53 and its activation of
negative feedback loops signifies the importance of keeping p53 tightly regulated after
DNA damage. PSPs play a role in regulating p53 through direct dephosphorylation via
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PP1 and PP2A as well as enhancement of Mdm2 negative regulation of p53 through
PP2A.

DNA Damage Response Proteins Whose Activities are Enhanced
In contrast to the many instances of negative regulation of DDR proteins by PSPs,
there are also specific cases in which certain phosphatases enhance the activity of
proteins in the pathway (Figure 4).

ATM
PP5 has been shown to play an important role in the activation of the DDR
through ATM. Cells with decreased PP5 protein or activity exhibited a decrease in ATM
autophosphorylation at S1981, a decrease in ATM kinase activity, and a phenotype of
RDS after DNA damage, which is consistent with the phenotype of cells lacking ATM
activity (4). PP5-deficient MEFs displayed a defect in the G2/M checkpoint after IR, a
decrease in ATM activity, and less phosphorylation of ATM targets CHK2 and Nbs1
after DNA damage (207). In fact, PP5 was found to bind to ATM, and this binding was
increased after treatment with NCS or IR (4).
Interestingly, ATM plays a role in activating PP1 and this is important for the
G2/M checkpoint. It has been shown that PP1 is activated following DNA damage
caused by IR (59). ATM phosphorylates the PP1 inhibitor I-2 at S43, causing
dissociation of PP1 and I-2. This phosphorylation is necessary for the dephosphorylation
of PP1 at T320 (183). These two actions cause an increase in PP1 activity (59, 183).
PP1 then inhibits Aurora-B kinase activity resulting in a G2/M checkpoint (183).
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ATR
HIV-1 Vpr (viral protein R) induces a G2 checkpoint through ATR and the
phosphorylation of Cdk1 at Y15 (43, 65, 145, 149). PP2A is necessary for this Vprinduced checkpoint. Inhibition of PP2A with OA or knockdown of the PP2A A or C
subunits resulted in a decrease in the amount of cells arrested at the Vpr-induced G2/M
checkpoint, a decrease in Vpr-induced Cdk1 Y15 phosphorylation, and a decrease in
phosphorylation of CHK1 S345 (43, 111). This was only in a Vpr-induced fashion, as
PP2A had no effect on pS345-CHK1 after UV or HU (91).
In addition to its role in activating ATM, PP5 was also shown to be important for
the activation of ATR. PP5 can bind to ATR after treatment with NCS, UV, and HU.
PP5 was necessary for the phosphorylation of CHK1 at S345 and the knockdown of PP5
inhibited the replication checkpoint after UV, inhibited the S-phase checkpoint after HU,
and decreased RPA phosphorylation and foci formation (211).

DNA-PK
PP1, PP2A, and PP6 have all been shown to positively influence DNA-PK
activity. When PP1 was added to DNA-PK complexes that were induced to
autophosphorylate, the reduction in activity and disruption of the DNA-PK-DNA binding
due to the autophosphorylation were reversed (120). PP2A dephosphorylates DNA-PKcs
as well as Ku70 and Ku80 leading to increased DNA-PK activity (39). This opposes the
autophosphorylation of DNA-PK that results in decreased activity of DNA-PK (20).
CPT-induced DSB increased the association between PP2A and Ku proteins. PP2A
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dephosphorylation of DNA-PKcs and Ku increases the association between the DNA-PK
proteins and this promotes DNA repair (193).
PP6 and DNA-PK form a complex in cells and this binding increases after IR. IR
causes a translocation of DNA-PK and PP6 from the cytoplasm to the nucleus and it
appears that localization of the phosphatase is dependent on the kinase and vice versa.
Knockdown of PP6 almost completely abolished the increase in DNA-PK activity after
IR, caused a defect in DSB repair, and resulted in colongenic survival similar to DNA-PK
knockdown cells, which means they have a higher sensitivity to IR (123).

BRCA1
PP1 can dephosphorylate BRCA1 at the CHK2 site S988, the ATM site S1524,
and the ATR site S1423 (101, 208). The overexpression of PP1 can partially inhibit the
hyperphosphorylation of BRCA1 after IR (101). Since PP1 can dephosphorylate BRCA1
at sites that have been shown to be important for BRCA1 function, it was intriguing to
find that PP1 may actually act to enhance BRCA1 function. PP1 specifically binds to
BRCA1 amino acids 898-901 (KVTF) (197, 208). Mutation of this site negatively
affected HR and the localization of the HR factor Rad51 to the break site, which are
functions of BRCA1 (208). Interestingly, in human tissues, PP1 mRNA levels were
significantly higher in normal tissue as compared to sporadic breast tumors (197). This
implicates PP1 in the activation of BRCA1.
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P53
Although p53 is negatively regulated via multiple PSPs, its activity is also
enhanced by two phosphatases. PP2Cα overexpression increases p53 transcription
activity. The overexpression of PP2Cα inhibits cell proliferation, cell cycle progression,
and colony formation and induces apoptosis. These effects are partially p53-dependent
(133).
P53 phosphorylation at T55 leads to p53 degradation (94). PP2A containing the
B'γ1 or B'γ3 subunit dephosphorylates T55 in response to DNA damage which leads to
the inhibition of cell proliferation and transformation. In addition, protein levels of B'γ
subunits increase after IR (93).
In conclusion, recent literature has demonstrated that PSPs have important
functions in both the activation of the DDR and its negative regulation. Negative
regulation can mean keeping the protein in an inactive state or inactivating it following
the repair of the DNA to allow for recovery from the cell cycle checkpoint.

Summary and Rationale
The DDR is extremely important for cells to prevent the propagation of mutations
that can lead to cancer. A highly sophisticated network of cell signaling machinery
coordinates cell cycle checkpoints, DNA repair, senescence, and apoptosis. CHK2 plays
an integral role in the successful function of the DDR, especially in response to doublestrand breaks.
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PSPs are increasingly being discovered to influence the activities of DDR
proteins, both in positive and negative ways. We have decided to further examine the
role of CHK2 in the DDR and its regulation through its interactions with other proteins.
We have identified the B'α subunit of PP2A as a CHK2 interacting protein and
demonstrate that it negatively regulates CHK2 phosphorylation, activity, and protein
stability. This work provides a novel mechanism for CHK2 regulation and may be
important for checkpoint recovery.
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MATERIALS AND METHODS
Cloning
CHEK2 was cloned into the pGBKT7 vector via PCR of a human mammary
gland cDNA library (CLONTECH Laboratories).

PCR was used to generate B'α

fragments containing amino acid residues 1-486 (full length), 1-195, 1-322, 176-322,
176-486, 304-486, 44-322, 89-322, 133-322, 1-282, and 1-195 from the clone that was
identified in the yeast-two hybrid screen to bind to CHK2. These fragments were all
cloned into the pACT2 vector and the full-length was cloned into pCMV2-FLAG. PCR
was also used to generate fragments of CHK2 containing amino acid residues 1-303, 1194, 1-107, 89-194, 143-390, 195-336, 217-543, and 304-543. These were cloned into
the pGBKT7 vector. Full length CHK2 was subcloned into the pCMV-Tag3B vector.
The D347A, S33/35A, and S33/35E mutant forms of CHK2 were constructed via sitedirected mutagenesis and cloned into the pCMV-Tag3B and pcDNA3 vectors.

Yeast Two-Hybrid
The yeast-two hybrid was performed via the MATCHMAKER Two-Hybrid
System 3 (CLONTECH Laboratories), briefly described here. First, full length CHEK2
in pGBKT7 was transformed into AH109 yeast and selection was made on SD -Trp
media. Next, the human mammary gland library (CLONTECH Laboratories) in the
pACT2 vector was transformed into the same yeast and selection was made on SD -Leu Trp -Ade -His minimal media to verify binding between CHK2 and any prey from the
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library. For the deletion fragment analysis, the full length gene encoding B'α in pACT2
was co-transformed with each CHEK2 fragment in pGBKT7 or full length CHEK2 in
pGBKT7 was transformed with each B'α gene fragment in pACT2 into AH109 yeast and
selection was made on minimal media.

Cell Culture, Transfection, and Reagents
293T cells were grown in DMEM media (Sigma) supplemented with 7.5% Fetal
Bovine Serum (SAFC), 1% Penicillin Streptomycin (Gibco), and 0.5% Amphotericin-B
(Sigma). HCT15 cells were grown in RMPI media (Gibco; Sigma) supplemented with
10% Fetal Bovine Serum, 1% Penicillin Streptomycin, and 0.5% Amphotericin-B.
HCT116 wild type (WT) and HCT116 CHK2-/- cells were a gift from Bert Vogelstein and
they were maintained in McCoy's 5A media (Gibco) supplemented with 10% Fetal
Bovine Serum, 1% Penicillin Streptomycin, and 0.5% Amphotericin-B. 293T cells were
transfected using Fugene 6 (Roche) and the HCT15 and HCT116 CHK2-/- cells were
transfected using Lipofectamine 2000 (Invitrogen). When indicated, cells were treated
with wortmannin, okadaic acid, hydroxyurea, mitomycin C, or doxorubicin (all from
Sigma) at the indicated concentrations.

Immunoprecipitations
For endogenous co-immunoprecipitations, 293T cells were lysed with RIPA
buffer (10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA pH 8.0, 1% Triton X-100, 0.1%
sodium deoxycholate, 0.1% SDS) or NETN buffer (20 mM Tris pH 8.0, 150 mM NaCl, 1
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mM EDTA, 0.5% NP-40, 1X protease inhibitors (Sigma), 1 mM PMSF, 0.5 mM Sodium
Vanadate, 0.5 mM Sodium Molybdate) and incubated with an antibody to CHK2 and
Protein A/G PLUS-Agarose (Santa Cruz) in modified RIPA buffer (made without sodium
deoxycholate and SDS) or NETN. Samples were eluted via boiling in sample buffer and
analyzed by immunoblotting. For co-immunoprecipitations with overexpressed proteins,
293T cells were transfected with a pCEP-4HA plasmid containing B'α, B'β, B'δ, B'ε, or
B'γ3 (obtained from Addgene; originally deposited by D. Virshup), a pCMV2-FLAG
plasmid containing B'α, or co-transfected with pCMV2-FLAG-B'α and wild-type CHK2
or a mutated CHK2 construct in pcDNA3. For immunoprecipitations via the HA tag,
cells were lysed with NETN buffer and incubated overnight with monoclonal anti-HA
agarose conjugate (Clone HA-7; Sigma). Samples were eluted via boiling in sample
buffer and analyzed by immunoblotting. For immunoprecipitations via the FLAG tag,
lysates were incubated with anti-FLAG M2 Affinity Gel (Sigma). Samples were eluted
with 150 ng/µL 3X FLAG peptide (Sigma) and analyzed by immunoblotting.

Immunoblotting
Cell lysis was performed with NETN buffer. Samples were incubated on ice for
15 min and then centrifuged for 20 min at 13,000 rpm at 4ºC. Lysates were separated by
SDS-PAGE gel and transferred to PVDF membranes. Membranes were immunoblotted
using the following antibodies: CHK2 (Clone 7; Upstate), CHK2 (NT; ProSci, Inc.),
PP2A A (Clone H-300; Santa Cruz), PP2A C (Clone 1D6; Upstate), PP2A B' (Upstate),
CHK1 (Clone G4; Santa Cruz), CHK2 phospho-serine 19 (Cell Signaling), CHK2
phospho-serines 33/35 (Cell Signaling), CHK2 phospho-threonine 68 (Cell Signaling),
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CHK1 phospho-serine 317 (Cell Signaling), Talin (Clone TA205; Upstate), PARP (BD
PharMingen), H2AX (Upstate), FLAG (M2, peroxidase conjugate; Sigma), β-actin
(Clone AC-74; Sigma), HA (Clone 3F10; Roche). Immobilon Western
Chemiluminescent HRP Substrate (Millipore) or Amersham ECL Plus Western Blotting
Detection Reagent (GE Healthcare) was used for detection.

Kinase Activity Assay
293T cells, 293T cells transiently transfected with pCMV2-FLAG empty vector
or one containing FLAG-B'α, or HCT15 cells transiently transfected with a pCMVTag3B empty vector or one containing myc-tagged CHK2 WT, D347A, S33/35A, or
S33/35E were irradiated with 20 Gy IR or mock treated. Cells were lysed with NETN
buffer and immunoprecipitated using an antibody to CHK2 or the c-Myc tag (Clone
9E10; Santa Cruz) and Protein A/G PLUS-Agarose (Santa Cruz). Immunoprecipitates
were washed with NETN followed by kinase assay buffer (50 mM Tris-HCl pH7.5, 10
mM MgCl2, 2 mM dithiothreitol, 1X protease inhibitors (Sigma), 1 mM PMSF, 0.5 mM
sodium vanadate, 0.5 mM sodium molybdate). Kinase reactions were carried out at 30ºC
for 30 min in kinase assay buffer containing 25 µM ATP and 10 µCi [γ-32P]ATP with
either 2 µg GST-B'α or 1 µg of GST-Cdc25C (amino acids 200-256) as a substrate using
equivalent amounts of GST as a negative control. Reactions were stopped by addition of
sample buffer, boiled, and separated by SDS-PAGE gels which were then immunoblotted
for CHK2 and autoradiographed. The plasmid containing GST-Cdc25C (amino acids
200-256) was a gift from Larry Karnitz (154).
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Subcellular Fractionation
Cells were fractionated into cytoplasmic, nucleoplasmic, and chromatin fractions
using a modified EMSA protocol (146). Buffer A (20 mM Tris pH 7.4, 10% glycerol, 10
mM KCl, 0.2% NP-40, 1 mM EDTA, 1X protease inhibitors (Sigma), 1 mM PMSF, 0.5
mM Sodium Vanadate, 0.5 mM Sodium Molybdate, 0.6 mM β-mercaptoethanol) was
added to cells, mixed by flicking, and left on ice for 15 min. Samples were spun down
for 2 min at 14,000 rpm at 4ºC and the supernatant was saved as the cytoplasmic fraction.
The pellet was washed once with Buffer A, then Buffer B (20 mM Tris pH 7.4, 20%
glycerol, 10 mM KCl, 400 mM NaCl, 1 mM EDTA, 1X protease inhibitors (Sigma), 1
mM PMSF, 0.5 mM Sodium Vanadate, 0.5 mM Sodium Molybdate, 0.6 mM βmercaptoethanol) was added and mixed by pipeting. Samples were incubated on a
rocking platform at 4ºC for 20 min then centrifuged at 14,000 rpm for 15 min at 4ºC.
The supernatant was saved as the nuclear fraction. Acid extraction buffer (0.5 M HCl,
10% glycerol, 100 mM β-mercaptoethanol) was added to the remaining pellet, vortexed,
incubated for 2 min, and centrifuged at 14,000 rpm for 5 min. Neutralization buffer (40
mM Tris pH 7.4, protease inhibitors) was added and the samples were adjusted to a pH of
7.4 and saved as the chromatin fraction. Immunoblot analysis was performed.

Phosphatase Activity Assay
Phosphatase activity was measured using the PP2A Immunoprecipitation
Phosphatase Assay Kit (Upstate) following the manufacturer's instructions. Briefly, cells
were lysed with NETN buffer and immunoprecipitated with an antibody to PP2A C (for
total PP2A activity) or FLAG (for activity of PP2A containing FLAG-B'α).
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Immunoprecipitates were incubated with a phosphopeptide for 10 min at 30ºC and free
phosphate was measured by addition of Malachite Green Detection Solution and the
absorbance levels were read at 650 nm.

Protein Stability
HCT15 cells were transiently transfected with a pcDNA3 plasmid containing
CHK2 WT, S33/35A, or S33/35E. 24 h later, 100 µg/mL cycloheximide was added to all
plates to inhibit new protein synthesis and the cells were mock-irradiated or irradiated
with 20 Gy IR and collected every two hours. The 0 h time point was mock-irradiated
only. Cells were lysed with NETN buffer and analyzed by immunoblotting.
AlphaEaseFC software (Alpha Innotech) was used for densitometry analysis of the
immunoblot bands. This data was plotted on a graph and the best-fit line was generated
to allow for comparison of the slopes of each line, which corresponds with the rate at
which the protein was being degraded.
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RESULTS
CHK2 Binds to the B'α Subunit of PP2A
While much is known about the signaling networks that function in the DDR, not
much is known about the negative regulation of the proteins involved in the absence of
damage as well as during recovery from the checkpoint. To this end, we decided to
identify novel interacting partners of CHK2 using the yeast two-hybrid system, identify
the binding domains, and verify the interaction in mammalian cells.

CHK2 Interacts with the B'α Subunit of PP2A in Yeast.
In order to identify novel interacting proteins of CHK2, we utilized the yeast twohybrid system. The full length CHEK2 gene was cloned into the pGBKT7 vector, which
expresses proteins fused to the GAL4 DNA binding domain and allows growth on media
lacking Tryptophan. We used this construct to screen a human mammary gland cDNA
library in the pACT2 vector, which expresses proteins fused to the GAL4 Activation
domain and allows growth on media lacking Leucine.

When there is an interaction

between the protein fused to the DNA binding domain and the protein fused to the
activation domain, this results in the expression of genes which allow growth on media
lacking Adenine and Histidine. Therefore, interacting partners of CHK2 were isolated
based on their ability, when co-expressed with wild-type CHK2, to allow yeast to grow
on media lacking Adenine, Histidine, Leucine, and Tryptophan.
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In this screening, we identified two independent clones of the B'α regulatory
subunit of PP2A (gene name: PPP2R5A). As proof that our CHK2 construct was
properly folded, we also identified two interacting proteins of CHK2 that have been
previously described: KPNA2 and Mus81. Karyopherin KPNA2 has been shown to bind
to a NLS of CHK2 and this interaction is important for proper CHK2 localization in the
nucleus (209). Mus81, a damage tolerance protein, was shown to bind to the FHA
domain of the S. pombe homologue of CHK2, Cds1, and appears to be important in the
function of the DNA damage response cell cycle checkpoints in response to UV and
replication stress (13).
To further investigate the interaction between B'α and CHK2, we mapped the B'α
interacting domain in CHK2. Multiple deletion constructs of CHEK2 were constructed
via PCR and cloned into the pGBKT7 vector. Each was co-transformed with the pACT2
vector containing the full length B'α. Binding was determined using the yeast-two hybrid
system and was defined as growth of colonies on minimal media (-Ade, -His, -Leu, -Trp)
as in the original yeast two-hybrid screening. The minimal CHK2 fragment that bound to
full length B'α was comprised of amino acid residues 1-107. This region contains the
entire SQ/TQ region (Figure 5), where ATM phosphorylates CHK2 at S19, S33, S35 and
T68, leading to the full activation of CHK2.
To determine the CHK2 binding region in B'α, multiple deletion constructs were
constructed of B'α in pACT2 and each was co-expressed with full length CHK2 in
pGBKT7. Binding was determined using the yeast-two hybrid system, again defined as
growth in minimal media. The minimal binding region in B'α was found to contain
amino acid residues 89-322 (Figure 6). Although this region spans almost half of the
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protein, the crystal structure of the PP2A holoenzyme containing B'γ1, which is closely
related to B'α, reveals unique features of this enzyme (25, 201). B'γ1 contains eighteen α
helices which form eight HEAT-like repeats and the interaction to the A and C subunits
is mediated by many residues scattered throughout the B'γ1 protein (201), as noted in
Figure 6. Therefore, it is probable that there are select residues within this span of amino
acid residues 89-322 that are particularly important for the interaction to CHK2.
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Figure 5. B'α binds to CHK2 amino acids 1-107. The full length CHK2 protein is
shown with phosphorylation sites and domains highlighted. The SQ/TQ domain is
displayed in light gray, the FHA domain in dark gray, and the kinase domain in black.
Using the yeast two-hybrid system, deletion mutants of CHK2 were co-transformed into
yeast with full-length B'α.
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Figure 6. CHK2 binds to B'α amino acids 89-322. Full length B'α is shown with the
residues responsible for binding to the PP2A A subunit in light gray and the C subunit in
dark gray (201). Using the yeast two-hybrid system, deletion mutants of B'α were cotransformed with full-length CHK2.
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CHK2 and B'α Bind in Mammalian Cells
We next wanted to verify the binding of B'α and CHK2 in a mammalian system.
293T cells were transiently transfected to express FLAG-B'α. Whole cell extracts were
immunoprecipitated using a FLAG antibody and eluted using an excess of FLAG
peptide. This prevents the appearance of the heavy and light chains of the
immunoglobulin on the Western blot and significantly reduces background. The
immunoprecipitate was immunoblotted for endogenous CHK2, demonstrating that B'α
and CHK2 interact in vivo (Figure 7).

Immunoblotting also detected the endogenous

PP2A A and C subunits, indicating that FLAG-B’α is able to function as a member of the
potentially active heterotrimeric PP2A complex.
To ensure that the binding of CHK2 with B'α occurs without overexpression of
the B'α protein, immunoprecipitation of the endogenous proteins was utilized. Whole
cell lysates of 293T cells were immunoprecipitated using a CHK2 antibody and were
then analyzed via Western blot using an antibody to B'α. As shown in Figure 8, B'α was
able to bind to CHK2, verifying that this interaction occurs with the endogenous levels of
both proteins.
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Figure 7. CHK2 binds to FLAG-B'α in mammalian cells. Whole cell lysates of 293T
cells expressing FLAG-B'α were immunoprecipitated (IP) using the FLAG antibody and
immunoblotted (IB) for the indicated proteins. Cell lysates that were not expressing
FLAG-B'α were used as a negative control.
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Figure 8. Endogenous CHK2 and endogenous B'α bind in mammalian cells. Whole
cell lysates of 293T cells were immunoprecipitated using an antibody to CHK2 and
immunoblotted for B'α. Normal mouse IgG was used as a negative control for the
immunoprecipitation.
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Binding Between CHK2 and PP2A is Modulated by DNA Damage
It is well characterized that CHK2 is activated upon the induction of DNA
damage and this involves the phosphorylation of CHK2 at multiple sites, including the
region that binds to B'α. Therefore, we determined whether the binding between CHK2
and B'α is modified under these conditions. We also determined the extent to which
CHK2 could bind other members of the B' family and the PP2A C catalytic subunit.

B'α and CHK2 Dissociate upon IR-Induced DNA Damage.
Since CHK2 is activated upon DNA damage, we examined the binding between
CHK2 and B'α for any changes upon the induction of DNA DSB by exposing cells to IR.
Whole cell extracts of 293T cells transiently expressing FLAG-B'α were
immunoprecipitated using a FLAG antibody and immunoblotted for endogenous CHK2,
PP2A A and PP2A C (Figure 9). Interestingly, when cells were exposed to 20 Gy IR and
incubated for 1 h, this markedly reduced the binding of CHK2 to B'α without affecting
the binding of B'α to the PP2A A and C subunits.
Phosphorylation of CHK2 serine 33 and 35 is recognized by the same antibody
and therefore we will refer to them as S33/35. Immunoblotting of the lysate input verifies
that IR causes phosphorylation of CHK2 at S19, S33/35, and T68 as previously described
(3, 16, 113, 119), verifying the activation of CHK2 after IR (Figure 9).
To ensure that the dissociation seen between CHK2 and B'α in the previous
experiment was not an artifact of the antibody that was used, we repeated the experiment
but immunoblotted with a different CHK2 antibody from another company. Again,
CHK2 was seen to bind to B'α under normal conditions and after exposure to IR, CHK2
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and B'α were dissociated (Figure 10). This confirms that CHK2 and B'α are dissociated
after IR and this is not due to specific reagents that were used.
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Figure 9. Binding between CHK2 and B'α is disrupted after DNA damage. 293T
cells transiently expressing FLAG-B'α or empty vector (FLAG) were irradiated with 20
Gy and incubated for 1 h. Whole cell lysates were immunoprecipitated using a FLAG
antibody and immunoblotted for the indicated proteins. The CHK2 antibody used is antiCHK2 (clone 7) from Upstate Cell Signaling Solutions.
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Figure 10. Dissociation of CHK2 and B'α is verified using another CHK2 antibody.
293T cells transiently expressing FLAG-B'α were irradiated with 20 Gy and incubated
for 1 h. Whole cell lysates were immunoprecipitated using a FLAG antibody and
immunoblotted for the indicated proteins. The CHK2 antibody used is anti-CHK2 (NT),
from Pro Sci, Incorporated.
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CHK2 Binds to Many PP2A Subunits.
We have determined that CHK2 binds to one member of the PP2A B' family,
namely B'α. The B' family of regulatory subunits is comprised of at least nine members
encoded from five genes. To determine the specificity of CHK2 for additional B'
proteins, HA-tagged B'α, B'β, B'δ, B'ε, and B'γ3 proteins were transiently expressed in
293T cells. Whole cell lysates were immunoprecipitated via an antibody to the HA tag.
Endogenous CHK2 was efficiently immunoprecipitated by all of the B’ proteins tested
(Figure 11), in agreement with a previous study that demonstrated CHK2's ability to bind
to many B' proteins using an in vitro binding assay (40). In our study, CHK2 had the
strongest interaction to B'γ3 and the weakest to B'β, with binding to B'α, B'δ, and B'ε
residing within this range. Additionally, the CHK2-B' complexes were dissociated after
the cells were exposed to IR. It should be noted that the ability of the B'β protein to bind
to the PP2A A and C subunits was compromised compared to the other B' proteins,
suggesting there may be a problem with the conformation of this overexpressed B'β.
In order to determine whether CHK2 can bind to an active PP2A complex, we
immunoprecipitated CHK2 from the whole cell lysates of 293T cells and immunoblotted
for the PP2A C catalytic subunit (Figure 12). Indeed, endogenous CHK2 was able to
bind to endogenous PP2A C, suggesting that CHK2 can associate with an active PP2A
complex through one of the B' regulatory subunits. After the cells were exposed to IR to
induce DNA damage, the binding between CHK2 and PP2A C is severely diminished, as
was seen with the B' subunits.
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Figure 11. CHK2 binds to many PP2A B' subunits and they are dissociated after
IR. 293T cells transiently transfected with HA-tagged B'α, B'β, B'δ, B'ε or B'γ3 were
irradiated with 20 Gy and incubated for 1 h. Whole cell lysates were immunoprecipitated
with the HA antibody and immunoblotted for the indicated proteins. CHK2 was able to
bind to all B' proteins tested and all were at least partially dissociated by exposure to IR.
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Figure 12. Endogenous PP2A C and CHK2 can bind and they are dissociated after
IR. 293T cells were irradiated with 20 Gy and incubated for 1 h. Whole cell lysates
were immunoprecipitated with an antibody to CHK2 and immunoblotted for PP2A C.
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B'α and CHK2 are Dissociated After DNA Damage Caused by IR and Doxorubicin, but
not B'α and CHK1
CHK2 can be activated by other types of DNA damage in addition to DSB caused
by IR. Therefore, other DNA damaging agents were also tested for any effects on the
binding between CHK2 and B'α. 293T cells transiently expressing FLAG-B'α were
exposed to IR, UV, HU, mitomycin C (MMC), or doxorubicin (Dox). FLAG-B'α was
immunoprecipitated and immunoblotted for endogenous CHK2, PP2A A and PP2A C.
Interestingly, treatment with UV, HU, or MMC did not have any effect on the ability of
CHK2 to bind to FLAG-B'α (Figure 13). However, treatment with Dox did decrease the
binding between the two proteins, but not to the extent that IR did. By examining the
phosphorylation of CHK2 in the lysate input via immunoblotting, it can be seen that the
pattern of CHK2 phosphorylation was different after each treatment. After IR and Dox,
S19, S33/35, and T68 were all phosphorylated; after UV and MMC, T68 was primarily
phosphorylated and S19 was weakly phosphorylated; and after HU, S19 and T68 were
phosphorylated. The dissociation between CHK2 and B'α occurs after IR and Dox: the
only conditions that resulted in S33/35 phosphorylation at the time points studied.
Since CHK1 is also phosphorylated and activated in response to DNA damage in
a similar manner to CHK2, we also tested whether CHK1 could bind to PP2A B'α and
whether this binding was disrupted by DNA damage (Figure 13). Interestingly, CHK1
was able to bind to B'α, but this binding was not disrupted by treatment with IR, UV,
HU, MMC, or Dox. CHK1 was highly phosphorylated at S317 after IR, UV, and HU,
which is in agreement with previous studies (53, 213).

This demonstrates that the

modulation of the interaction by DNA damage is specific to the CHK2-B'α complex.
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Figure 13. Dissociation of CHK2 and B'α is caused by DNA damage induced by IR
and doxorubicin. 293T cells transiently transfected with FLAG-B'α were exposed to
either 20 Gy IR and incubated for 1 h, 50 J/m2 UV and incubated for 2 h, 2 mM
hydroxyurea (HU) for 24 h, 0.5 µg/mL mitomycin C (MMC) for 24 h, or 1 mM
doxorubicin (DOX) for 2 h. Whole cell lysates were immunoprecipitated using the
FLAG antibody and immunoblotted for the indicated proteins.
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Analysis of the IR-Induced Dissociation of CHK2 and B'α
The previous experiments have demonstrated that CHK2 can bind to many B'
family members as well as the C subunit and they are dissociated after specific types of
DNA damage. Since the dissociation of CHK2 and B'α occurs the most after treatment
with IR, we decided to further characterize this dissociation by examining any dose
dependence, the timing of dissociation, and whether they could re-associate at later points
in time. We also examined the role of phosphorylation in the binding and dissociation of
CHK2 and B'α since the dissociation correlated with the phosphorylation of CHK2 at
certain sites.

Dissociation is an Early Event and Occurs in a Dose-Dependent Manner
Since we have observed that IR causes the most dissociation of B'α and CHK2 of
all of the DNA damaging agents that we studied, we next ascertained which doses of IR
provide maximal dissociation. 293T cells transiently expressing FLAG-B'α were
exposed to 2, 5, 10, 20, or 50 Gy, and FLAG-B'α was immunoprecipitated and
immunoblotted (Figure 14). Maximal dissociation of endogenous CHK2 and B'α
reached a peak after exposure to 10 Gy IR. By examining the phosphorylation of CHK2
in the lysate input, it can be seen that S19 phosphorylation increased with the increasing
doses of IR. T68 phosphorylation was maximal after 2 and 5 Gy, and then decreased
with the increasing IR doses. However, we observed the phosphorylation of S33/35 to be
maximal after 10 Gy of IR. This corresponds to the IR dose that induces maximal
dissociation between CHK2 and B'α.
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In order to determine the precise timing of B'α and CHK2 dissociation after IR,
293T cells transiently expressing FLAG-B'α were irradiated with 20 Gy IR and collected
every half an hour from 0.5 h to 2.5 hours following IR. FLAG-B'α was
immunoprecipitated and it was found that CHK2 binding was minimal 0.5 h after IR, and
the binding was slightly restored over the remainder of the time course (Figure 15).
Significantly, the dissociation at 0.5 h correlated with maximal phosphorylation of CHK2
at S33/35, but did not correlate with phosphorylation of S19 or T68.
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Figure 14. Dissociation of CHK2 and B'α occurs in a dose-dependent manner.
293T cells were transiently transfected with FLAG-B'α and irradiated with 2, 5, 10, 20,
or 50 Gy and incubated for 1 h. Whole cell lysates were immunoprecipitated with the
FLAG antibody and immunoblotted for the indicated proteins.
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Figure 15. Dissociation of CHK2 and B'α is an early event after IR. 293T cells were
transiently transfected with FLAG-B'α and irradiated with 20 Gy and incubated for 0.5,
1.0, 1.5, 2.0, or 2.5 h. Whole cell lysates were immunoprecipitated with the FLAG
antibody and immunoblotted for the indicated proteins.
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Re-Association of CHK2 and B'α does Not Correlate With Resolution of DNA Damage
CHK2 plays an important role in activating cell cycle checkpoints after DNA
damage (8). Since we have established that PP2A B'α and CHK2 dissociate after IR, we
investigated whether re-association at a later time was correlated to the resolution of
DNA damage. We used two different doses of IR for comparison. First, we exposed cells
to a sub-lethal dose of 6 Gy, the lowest dose after which we could detect a significant
dissociation between CHK2 and B'α and which would also allow for recovery. We also
exposed the cells to 50 Gy, which is considered lethal. 293T cells expressing FLAG-B'α
were collected 1 h, 4 h, 8 h, and 12 h after exposure to both doses of IR (Figure 16 and
Figure 17). Interestingly, the kinetics of dissociation after 50 Gy were similar to that
after 6 Gy. CHK2 was dissociated from B'α after 1 h and began to re-associate
approximately 4 h after IR with a subsequent increase through the remaining time points.
After both doses, the phosphorylation of S19, S33/35, and T68 followed similar patterns.
S33/35 had maximal phosphorylation after 1 h, again correlating with the most
dissociation between CHK2 and B'α. There does seem to be some difference in CHK2
phosphorylation between the two doses, since after 6 Gy IR, the CHK2 that was bound to
B'α after 4-12 h existed as a doublet, suggesting the existence of hyper and
hypophosphorylated forms (Figure 16).
In order to assess how dissociation and re-association correlated with the
resolution of DNA damage, we determined the levels of histone H2AX phosphorylated at
S139, also known as γ-H2AX, which is a well characterized marker of DSB (148). Thus,
higher levels of γ-H2AX denote the presence of DSB. When the breaks are repaired, γH2AX levels return to levels found before DNA damage (in some cases it can no longer
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be detected by Western blot or immunofluorescence). In our experiments, after 6 Gy IR,
the maximal amount of γ-H2AX appeared after 4 h, returning to pre-damage levels by 12
h (Figure 16). On the other hand, after 50 Gy IR, maximal levels of γ-H2AX were
detected after 1 h and did not decline throughout the remainder of the time points (Figure
17). Since B'α and CHK2 were shown to re-associate throughout the time course, and
DNA DSB were present during these times as show by the presence of γ-H2AX, the reassociation does not correlate with the resolution of the DSB.
In summary, dissociation of CHK2 and B'α is induced in a dose-dependent
manner and is an early event after IR. CHK2 and B'α re-association after DNA damage
does not require resolution of the DNA damage. Moreover, dissociation and reassociation correlate with phosphorylation of S33/35 of CHK2.
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Figure 16. CHK2 and B'α are able to re-associate hours after 6 Gy IR. 293T cells
were transiently transfected with FLAG-B'α and irradiated with 6 Gy and incubated for
1, 4, 8, or 12 h. Whole cell lysates were immunoprecipitated with the FLAG antibody
and immunoblotted for the indicated proteins.
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Figure 17. CHK2 and B'α are able to re-associate hours after 50 Gy IR. 293T cells
were transiently transfected with FLAG-B'α and irradiated with 50 Gy and incubated for
1, 4, 8, or 12 h. Whole cell lysates were immunoprecipitated with the FLAG antibody
and immunoblotted for the indicated proteins.
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The Activity of ATM, but not PP2A, is Necessary for the Dissociation of CHK2 and B'α.
We next investigated the importance of PP2A activity on the binding and
dissociation of CHK2 and B'α. OA is a phosphatase inhibitor that, when used at 0.5 µM,
blocks the PP2A catalytic subunit's activity without affecting PP1 (55). 293T cells
transiently expressing FLAG-B'α were treated with OA prior to IR exposure. FLAG-B'α
was immunoprecipitated using an antibody to the FLAG tag and immunoblot analysis
was performed (Figure 18). In the mock treated cells, CHK2 was able to bind to FLAGB'α, and this binding was unaffected by OA treatment alone. After IR, CHK2 and B'α
dissociated and the presence of OA did not affect the dissociation. The inhibition of
PP2A by OA also had no effect on the ability of FLAG-B'α to bind to the PP2A A and C
subunits, indicating that it can still form the holoenzyme complex. Therefore, PP2A
activity is not required for B'α binding to, or dissociation from, CHK2.
As we have seen thus far, the most pronounced dissociation between CHK2 and
B'α occurs when CHK2 is phosphorylated on S33/35, which are phosphorylated in an
ATM-dependent manner (16, 79, 124). ATM belongs to the PIKK family along with
ATR and DNA-PK. To determine whether the CHK2-B'α dissociation is a PIKKdependent event as is the phosphorylation of CHK2 S33/35, the PIKK inhibitor
wortmannin was utilized at a concentration that inhibits ATM and DNA-PK, but not ATR
activity in vivo (155). 293T cells transiently expressing FLAG-B'α were incubated with
wortmannin prior to exposure to IR. FLAG-B'α was immunoprecipitated using a FLAG
antibody and immunoblot analysis was performed (Figure 19). Pre-incubation with
wortmannin prevented the dissociation of CHK2 from FLAG-B'α after IR. This
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treatment also inhibited the phosphorylation of S19 and S33/35, indicating that the
phosphorylation of CHK2 is required for the dissociation of CHK2 and B'α.
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Figure 18. PP2A phosphatase activity is not required for CHK2 binding to or
dissociating from B'α. 293T cells were transiently transfected with FLAG-B'α, treated
with 0.5 µM OA for 1 h and then irradiated with 20 Gy IR and incubated for 1 h. Whole
cell lysates were immunoprecipitated with the FLAG antibody and immunoblotted for the
indicated proteins.
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Figure 19. Inhibition of ATM and DNA-PK kinase activity prevents the IR-induced
dissociation of B'α and CHK2. 293T cells were transiently transfected with FLAG-B'α,
treated with 20 µM wortmannin for 1 h then irradiated with 10 Gy IR and incubated for 1
h. Whole cell lysates were immunoprecipitated with the FLAG antibody and
immunoblotted for the indicated proteins.
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Mutation of CHK2 Serines 33 and 35 Affects Binding to B'α
To further investigate the importance of the phosphorylation of CHK2 S33/35 on
the binding and dissociation between CHK2 and B'α, we made two CHK2 mutants. The
substituted alanines for serines 33 and 35 to prevent phosphorylation (S33/35A) and the
substituted glutamic acids to mimic phosphorylation (S33/35E). Wild-type CHK2
(CHK2 WT), S33/35A and S33/35E were co-transfected along with FLAG-B'α into
HCT116 CHK2-/- cells, which were then mock-irradiated or irradiated with 20 Gy.
FLAG-B'α was immunoprecipitated and immunoblot analysis was performed (Figure
20). In mock treated cells, we saw an increase in S33/35A binding to B'α and a decrease
in S33/35E binding as compared to CHK2 WT. Alternatively, after irradiation, CHK2
WT and S33/35A bound at the same levels as mock treated CHK2 WT, however,
S33/35E binding is completely abrogated.
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Figure 20. Mutation of CHK2 serines 33 and 35 affects binding to B'α. HCT116
CHK2-/- cells were transfected with FLAG-B'α and either wild-type CHK2 or the
S33/35A or S33/35E mutants. Whole cell lysates were immunoprecipitated with the
FLAG antibody and immunoblotted for CHK2.
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Analysis of the Effects of CHK2 on PP2A
Thus far, we have documented the binding between CHK2 and many PP2A
subunits. This is an interesting case in which a kinase and a phosphatase bind under
certain circumstances. As described above in detail, CHK2 phosphorylates a number of
substrates which can positively and negatively regulate them. PSPs play important roles
in both positively and negatively regulating DDR proteins as well. Therefore, it is
possible that CHK2 kinase activity has an effect on PP2A activity, and vice versa. In this
next section, we will investigate whether PP2A B'α can be used as a substrate by CHK2
and the extent to which CHK2 or DNA damage could affect PP2A localization or
activity.

CHK2 can Phosphorylate B'α in vitro.
Since CHK2 is a kinase that is activated after irradiation, we determined whether
B'α could be used as a substrate for CHK2 in an in vitro kinase assay. 293T cells were
irradiated to activate CHK2 which was then immunoprecipitated and incubated in a
kinase reaction with GST-B'α (Figure 21). Indeed, phosphorylated B'α was detected,
indicating that in an in vitro system, CHK2 can phosphorylate B'α.
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Figure 21. CHK2 can phosphorylate B'α in vitro. Whole cell lysates from irradiated
293T cells were immunoprecipitated using an antibody to CHK2. CHK2 kinase activity
towards GST-B'α was measured using an in vitro kinase reaction.
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PP2A Localization is Not Influenced by IR
Since CHK2 was able to phosphorylate B'α in vitro, we next determined if this
had an effect on PP2A localization. 293T cells transiently expressing FLAG-B'α were
mock-irradiated or irradiated with 20 Gy, separated into the cytoplasmic, nucleoplasmic
and chromatin fractions, and subjected to immunoblot analysis (Figure 22). CHK2 was
located in the cytoplasm and nucleoplasm. The slower migrating form of CHK2 after IR
is indicative of its hyperphosphorylated active status. The PP2A A and C subunits were
also found in the cytoplasm and nucleoplasm, whereas FLAG-B'α was located in all three
cellular compartments. The localization in the chromatin fraction may be an effect of its
overexpression, as the endogenous A and C subunits could not be detected. Exposure of
the cells to IR did not change the localization of any proteins examined, indicating that
PP2A localization is not affected by DNA DSB caused by IR.
CHK2 was also found to bind to other B' family members in addition to B'α.
Therefore, using an antibody that recognizes many B' proteins, we also examined the
subcellular localization of the endogenous B' family. As seen in Figure 23, there are
endogenous B' proteins that are located in the cytoplasm and nucleoplasm, and the
localization of each protein is not affected by exposure of the cells to IR.
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Figure 22. B'α localization is not changed by IR. 293T cells transiently expressing
FLAG-B'α were mock-irradiated or irradiated with 20 Gy and incubated for 1 h. Using a
subcellular fractionation method, cells were separated into the cytoplasmic,
nucleoplasmic, and chromatin fractions, and immunoblot analysis for the indicated
proteins was performed. Talin was used as a marker for the cytoplasm, PARP for the
nucleoplasm, and H2AX for the chromatin.
80

Figure 23. Localization of endogenous PP2A proteins do not change after IR. 293T
cells were mock-irradiated or irradiated with 20 Gy and incubated for 1 h. Using a
subcellular fractionation method, cells were separated into the cytoplasmic,
nucleoplasmic, and chromatin fractions, and immunoblot analysis for the indicated
proteins was performed. Talin was used as a marker for the cytoplasm, PARP for the
nucleoplasm, and H2AX for the chromatin.
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PP2A Activity is Unaffected by IR and is Not Influenced by CHK2
If CHK2 is indeed able to phosphorylate B'α in vivo, it may have an effect on
PP2A activity. We first examined the total PP2A activity in the cell. The C subunit is
responsible for all of the PP2A catalytic activity in the cell, regardless of which
regulatory subunit is bound to the complex. Therefore, 293T cells were either exposed to
IR or mock treated and immunoprecipitated using an antibody to the C subunit to assess
total PP2A activity. Phosphatase activity of the immunoprecipitates was measured using
an in vitro phosphatase assay (Figure 24). The levels of PP2A activity were not changed
by exposure to IR.
Next, the activity of the PP2A complexes specifically containing FLAG-B'α was
determined. 293T cells transiently expressing FLAG-B'α were either exposed to IR or
mock treated and immunoprecipitated using a FLAG antibody to measure only the
activity of PP2A complexes containing B'α. Phosphatase activity was measured using an
in vitro phosphatase assay and was unaffected by exposure to IR (Figure 25). Since the
assay measures activity against a small peptide, this may not accurately reflect changes in
phosphatase activity toward specific substrates, however, it is a measure of the total
activity of PP2A containing the B'α subunit.
In order to determine whether CHK2 has an effect on PP2A activity, the HCT116
wild-type (WT) cells and the isogenic HCT116 CHK2-/- cell lines were utilized. Both
cell lines were either exposed to IR or mock treated and immunoprecipitated using an
antibody for the PP2A C subunit to measure total PP2A activity (Figure 26). The in
vitro phosphatase assay revealed no difference in PP2A activity in the mock treated or
irradiated samples in either cell line. Also, there was no difference observed between the
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HCT116 WT or CHK2-/- cell lines, suggesting that CHK2 has no effect on PP2A activity
under these conditions. Taken together, this data indicates that PP2A activity is not
affected by IR exposure or by CHK2.
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Figure 24. Total PP2A phosphatase activity does not change after IR. 293T cells
were irradiated with 20 Gy or mock treated and incubated for 1 h. Whole cell extracts
were immunoprecipitated with an antibody to the PP2A C subunit. Phosphatase activity
of the immunoprecipitates was determined using an in vitro phosphatase assay. The
activity of the mock sample was defined as 100%.
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Figure 25. Phosphatase activity of PP2A containing B'α does not change after IR.
293T cells transiently transfected with FLAG-B'α were irradiated with 20 Gy or mock
treated and incubated for 1 h. Whole cell extracts were immunoprecipitated using the
FLAG tag. Phosphatase activity was determined and the activity of the mock treated
sample expressing FLAG-B'α was defined as 100%.
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Figure 26. Total PP2A activity does not differ in HCT116 wild-type and CHK2-/cells. HCT116 wild-type and HCT116 CHK2-/- cells were irradiated with 20 Gy and
incubated for 1 h. Whole cell extracts were immunoprecipitated using an antibody to the
PP2A C subunit. Phosphatase activity was determined and the mock sample from the
HCT116 wild-type cells was defined as 100%.
86

Analysis of the Effects of PP2A on CHK2
We have shown that CHK2 does not seem to have any effect on PP2A activity or
localization, even though in vitro CHK2 can use B'α as a substrate. We next wanted to
determine the extent to which PP2A can affect CHK2 phosphorylation, activity, and
protein stability.

Changes in CHK2 Phosphorylation due to IR
In order to determine the extent to which PP2A has an effect on the
phosphorylation of CHK2, the PP2A inhibitor OA was utilized. 293T cells were treated
with OA in the presence and absence of irradiation, and the amount of phosphorylation of
CHK2 at specific sites was measured via immunoblotting (Figure 27). Pre-treatment
with OA increased the phosphorylation of CHK2 after IR, primarily at S19, although
there were also slight increases in the phosphorylation of S33/35 and T68, demonstrating
that PP2A can dephosphorylate CHK2 at multiple sites.
Since we have shown that mutation of S33/35 can influence the binding between
B'α and CHK2, this led us to investigate any effect phosphorylation at these sites has on
CHK2 function. Therefore, we examined the ability of the S33/35A and S33/35E
mutants to be phosphorylated at other CHK2 sites. HCT15 cells (which lack functional
CHK2) transiently expressing myc-tagged CHK2 wild-type (WT), kinase dead (D347A),
S33/35A, or S33/35E were either exposed to IR or mock treated. The phosphorylation
status of each CHK2 protein was determined via immunoblotting (Figure 28). In the
mock treated samples, CHK2 WT and S33/35A showed a very faint phosphorylation of
S19. However, S33/35E displayed a much stronger phosphorylation, even in the absence
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of DNA damage. After exposure to IR, CHK2 WT was phosphorylated on S19, with
levels comparable to the mock treated S33/35E. The phosphorylation of S33/35A at S19
was slightly compromised. T68 phosphorylation was slightly higher in the S33/35A and
S33/35E in both conditions as compared to CHK2 WT. Therefore, the S33/35 mutations
primarily affect S19 phosphorylation, the same site that was affected most by PP2A
inhibition.
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Figure 27. Inhibition of PP2A activity increases CHK2 phosphorylation. 293T cells
were incubated with 0.5 µM OA for 1 h then irradiated with 20 Gy and incubated for 1 h.
Whole cell extracts were examined for phosphorylation levels of CHK2 via immunoblot.
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Figure 28. Mutation of CHK2 serines 33 and 35 affects CHK2 phosphorylation at
other sites. HCT15 cells transiently transfected with pCMV-Tag3B empty vector
(vector) or myc-tagged CHK2 WT, D347A, S33/35A or S33/35E were exposed to 20 Gy
IR or mock treated and incubated for 1 h. Whole cell extracts were examined for CHK2
phosphorylation via immunoblot.
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Changes in CHK2 Kinase Activity after IR
To directly measure the affect of PP2A on CHK2 activity, we transfected 293T
cells with FLAG-B'α and measured CHK2 kinase activity using an in vitro kinase assay
with GST-Cdc25C (amino acid residues 200-256) as a substrate (Figure 29). Cells were
either mock treated or irradiated, CHK2 was immunoprecipitated, and the kinase activity
was measured. In the mock treated samples, B'α did not have any effect on CHK2 kinase
activity. However, after irradiation, overexpression of B'α prevented the full activation
of CHK2.
Since mutation of S33/35 to glutamic acid positively affects CHK2
phosphorylation primarily on S19, the effect on CHK2 kinase activity was also examined
since phosphorylation of this site has been shown to enhance CHK2 activity (16).
HCT15 cells expressing myc-tagged CHK2 WT, D347A, S33/35A, or S33/35E were
exposed to IR or mock treated. CHK2 activity was determined using an in vitro kinase
assay with GST-Cdc25C (amino acid residues 200-256) as a substrate (Figure 30). In
the mock treated samples, S33/35E had higher kinase activity than CHK2 WT, whereas
S33/35A had lower kinase activity. After IR, S33/35E had slightly higher kinase activity
than CHK2 WT, while the S33/35A mutant had significantly less. These data suggest
that phosphorylation of S33/35 is important for CHK2 activity and that mimicking this
phosphorylation can increase CHK2 activity even in the absence of DNA damage.
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Figure 29. B'α overexpression negatively affects CHK2 kinase activity. 293T cells
expressing FLAG-B'α or FLAG (as a negative control) were irradiated with 20 Gy and
incubated for 1 h. Whole cell lysates were immunoprecipitated using a CHK2 antibody
and incubated in an in vitro kinase assay using GST-Cdc25C (amino acids 200-256) as a
substrate. Autoradiographs (top panel) were normalized against the levels of CHK2
protein per sample and represented by graphs (bottom panel). 100% activity was defined
by the amount in the negative control sample after IR.
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Figure 30. Mutation of CHK2 serines 33 and 35 affects CHK2 kinase activity.
HCT15 cells were transiently transfected with empty vector (vector), CHK2 WT,
S33/35A, or S33/35E and mock-irradiated or exposed to 20 Gy IR and incubated for 1 h.
Cell lysates were immunoprecipitated and incubated in an in vitro kinase assay using
GST-Cdc25C (amino acids 200-256) as a substrate (top panel). Five experiments were
plotted on a single graph (bottom panel). Activity of 1 was defined as the activity in the
CHK2 WT mock-treated sample. The median of each set of data points is shown with a
black bar.
93

Mutation of CHK2 Serines 33 and 35 Affects Protein Stability
Another mode of CHK2 regulation is via its protein stability. CHK2 that is
expressed in HCT15 cells is phosphorylated at S456 after irradiation, stabilizing the
protein (75). Since we have shown that phosphorylation of S33/35 affects CHK2 kinase
activity, we also investigated the role it may play in protein stability. HCT15 cells
transiently expressing CHK2 WT, D347A, S33/35A, or S33/35E were incubated with
cycloheximide to prevent the synthesis of new proteins. Cells were then either exposed
to IR or mock treated and collected every two hours (Figure 31A). By plotting the bestfit line for each data set, the slope of the line could be examined to measure how fast the
protein is being degraded (Figure 31B). In mock treated cells, the S33/35E protein was
substantially more stable than WT. S33/35A had a slightly stabilizing effect as well.
After exposure to IR, the WT protein became more stable, whereas the stability of the
S33/35A and S33/35E proteins remained similar to the mock treated samples. These
results denote the importance of phosphorylations of S33/35 in the increase of CHK2
stability after IR.
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Figure 31A. Mutation of CHK2 serines 33 and 35 affects CHK2 protein stability.
HCT15 cells were transiently transfected with CHK2 wild-type (WT), S33/35A, or
S33/35E in the pcDNA3 vector. 100 µg/mL cycloheximide was added to all cells which
were then either mock treated or exposed to 20 Gy IR and collected at the indicated time
points. Levels of each protein were analyzed by immunoblotting.
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Figure 31B. Mutation of CHK2 serines 33 and 35 affects CHK2 protein stability.
Levels of CHK2 proteins from Figure 31A were normalized against the 0 h sample for
each condition and the best fit line was plotted for each data set. The slope of the mock
treated CHK2 WT line is -0.1250, S33/35A is -0.0831, and S33/35E is -0.0443. The
slope of the IR CHK2 WT line is -0.0733, S33/35A is -0.0738, and S33/35E is -0.0457.
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DISCUSSION
After DNA damage, the cell must activate cell cycle checkpoints to allow time to
repair the breaks, or if the damage is too extensive, trigger apoptosis signaling (214).
ATM phosphorylates CHK2 on multiple sites in the SQ/TQ domain, leading to full
CHK2 activation (3, 16, 79, 83, 113, 119, 124, 200). Here, we propose a novel
mechanism for CHK2 regulation in which ATM phosphorylation causes a dissociation of
PP2A from CHK2, thus allowing CHK2 activation. PP2A can then bind to CHK2 hours
later, providing a mechanism for CHK2 down-regulation after DNA damage (Figure 32).
We have identified the B'α subunit of PP2A as a CHK2-interacting protein via a
yeast two-hybrid screen and have confirmed the interaction in mammalian cells. Full
length CHK2 was found to bind to B'α amino acids 89-322. Our inability to further
narrow down the interacting region suggests that residues that mediate the interaction are
scattered within this region. Interestingly, the structure of the PP2A holoenzyme indicates
that the majority of interactions between the B' subunit and the A and C subunits are
mediated by amino acid residues located at intervening loops between the 18 α-helices
(25, 201). Thus, it is likely that this may also be the case for the interaction with CHK2.
Identification of these residues could reveal the basis for substrate specificity of PP2A
enzymes containing different B' subunits. This large portion of B'α that binds to CHK2
is a highly conserved region between the B' family members (42). Indeed, when we
tested the specificity of CHK2 for the B' family, we found that CHK2 could bind to B'β,
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B'δ, B'ε, and B'γ3 as well and all of the interactions were dissociated upon exposure to
irradiation.
In mammalian cells, binding between B'α and CHK2 is markedly decreased by
exposure to IR. However, other types of damage caused by UV, HU, or MMC did not
disrupt binding. Doxorubicin had an effect, but not to the extent to which IR did,
although comparisons of agents with different mechanisms of action are challenging. B'α
can also bind CHK1, though the interaction is not disrupted by any of the DNA damageinducing agents tested. This demonstrates a unique aspect of the relationship between
CHK2 and B'α: there is binding under normal conditions, but this is disrupted only after
DSB induced by IR, when serines 33 and 35 are phosphorylated. CHK2 and B'α are able
to re-associate hours after IR, and this correlates with the dephosphorylation of S33/35,
but not with repair of the bulk of damaged DNA as measured by phosphorylation of
histone H2AX.
We have found that maximal dissociation between CHK2 and B'α correlates with
maximal phosphorylation of CHK2 S33/35, which are phosphorylated in an ATMdependent manner (16). When we inhibited ATM with wortmannin, the phosphorylation
of S33/35 was prevented as well as the dissociation between CHK2 and B'α. The region
in CHK2 that binds to B'α is comprised of amino acids 1-107, which contains the entire
SQ/TQ domain. Serines 33 and 35 are located in this domain, suggesting that the
phosphorylation of these sites could directly contribute to the dissociation of the two
proteins. We therefore mutated CHK2 S33/35 to alanine to prevent phosphorylation
(S33/35A) or to glutamic acid to mimic phosphorylation (S33/35E) and tested the effects
on binding to B'α. Our data indicates that phosphorylation at S33/35 is necessary for the
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dissociation of B'α and CHK2, but it is not sufficient on its own; other phosphorylation
sites are probably involved as well. Interestingly, wild-type CHK2 did not dissociate
from B'α after IR when they were both overexpressed. This may be because when CHK2
is overexpressed, it can become activated without DNA damage, allowing for
dissociation in the absence of DNA damage (3, 200).
In mock treated cells, S33/35E had a level of phosphorylation at S19 that was
comparable to CHK2 WT after IR. Pharmacologic PP2A inhibition with OA also
increases phosphorylation at S19. Alternatively, the S33/35A mutant had slightly less
phosphorylation after IR compared to CHK2 WT. The S33/35E mutant also had
increased kinase activity in mock treated conditions compared to CHK2 WT.
Conversely, the S33/35A mutant had decreased kinase activity after IR, in agreement
with a previous study (16). CHK2 kinase activity is decreased when B'α is
overexpressed as well.
Mutations at S33/35 also altered CHK2 protein stability. The S33/35E mutant
was more stable as compared to the CHK2 WT under mock treated conditions. After
exposure to IR, the stability of the S33/35A and S33/35E proteins did not change;
however, the CHK2 WT protein stability increased after IR, in agreement with a previous
study that demonstrated CHK2 expressed in HCT15 cells is more stable after IR (75).
Our work demonstrates the importance of phosphorylation of S33/35 in this process.
PP2A has already been demonstrated to negatively regulate other DNA damage
response proteins under various conditions, including ATM, ATR, RPA, H2AX, CHK1,
and p53, signifying the importance of PP2A in the DNA damage response pathway (27,
28, 36, 48, 55, 88, 115, 121, 122, 128, 129, 142). In addition, two previous papers have
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implicated a role for PP2A in regulating CHK2. It was demonstrated that CHK2 can
phosphorylate B'γ in vitro, increasing PP2A activity towards CHK2 in vitro (40). In an in
vitro kinase assay, we found that CHK2 could phosphorylate B'α, however, this did not
have an effect on PP2A activity or localization. It has also been revealed that treating
cells with okadaic acid or incubating CHK2 protein with PP2A affected CHK2
phosphorylation at T68, in agreement with our results (96).
Another mode of CHK2 regulation in humans has been characterized. The Wip1
phosphatase has been shown to dephosphorylate T68 of CHK2 which leads to a decrease
in its kinase activity and ability to induce apoptosis (50, 136). Interestingly, Wip1
binding to CHK2 is enhanced by DNA damage, in opposition to the relationship between
PP2A and CHK2, which are dissociated after IR. Interestingly, both Wip1 and PP2A B'α
bind to the SQ/TQ domain of CHK2 (136, 206).
Mutations in CHEK2, the gene encoding the protein CHK2, have been associated
with various cancers. Since the main role of CHK2 in the cell is to prevent the
propagation of mutations via activation of DNA damage response cell cycle checkpoints,
any mutation that negatively affects CHK2 function might increase the likelihood that a
cell becomes cancerous. In fact, CHK2 mutations that cause decreased or eliminated
kinase activity, an inability to bind to substrates, inefficient phosphorylation on T68,
and/or destabilization of the protein have been identified (46, 85, 158, 169, 199). These
mutations are all located in the FHA domain, the kinase domain, or the region between
these two domains.
In the context of the interaction between CHK2 and PP2A, mutations at S33
and/or S35 that prevent the dissociation of PP2A and CHK2 would also prevent the full
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activation and stabilization of CHK2. To date, no mutations of S33/35 have been found
to be associated with cancer, even though they would negatively affect CHK2 function.
However, it cannot be assumed that because no mutations have been found specifically at
S33/35 that phosphorylation at these sites is not affected by mutations located elsewhere
in the protein. In fact, the 1100delC and E161del mutations have been shown to exhibit
inefficient phosphorylation of T68 in response to DNA damage (169). It will be
necessary to examine these and other cancer-associated CHK2 mutations for the affect
they have on the ability of CHK2 to be phosphorylated on S33/35 as well.
Not only have no mutations been found at S33/35, but no cancer-associated
mutations have been found in the entire SQ/TQ domain. It is not known how a mutation
in the SQ/TQ domain would affect the structure of the protein or the function of the
enzyme since this domain is unstructured and has not been crystallized (17). It is
possible that mutations in the SQ/TQ domain may prevent the binding of PP2A to CHK2
under normal circumstances, leading to an inappropriate activation of CHK2 that could
inhibit cell proliferation even in the absence of DNA damage.
Proper regulation of the DDR is important for cell function. Activation of the
DDR is necessary to prevent the propagation of mutations that could lead to diseases such
as cancer. Negative regulation of the DDR is important for the cell to prevent
inappropriate checkpoint signaling as well as returning the cell to the cell cycle after the
damage is repaired. Indeed, the multiple modes of CHK2 regulation, by two
phosphatases and by regulation of kinase activity and protein stability, may highlight this
importance.
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Figure 32. Model of PP2A regulation of CHK2 through binding and dissociation.
CHK2 binds to PP2A through the B'α subunit under normal conditions. IR-induced DSB
causes dissociation through ATM phosphorylation of CHK2 S33/35. When these are
dephosphorylated, PP2A can bind back to CHK2 and dephosphorylate it. This leads to
decreased CHK2 activity and protein stability.
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